



Clinical Trials on Alzheimer's Disease

11th

edition of

Clinical Trials on Alzheimer's Disease

PROGRAM

PALAU DE CONGRESSOS DE CATALUNYA

Barcelona, October 24-27, 2018



Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17

www.ctad-alzheimer.com



BARCELONA, SPAIN

Organizing and Scientific Committees	p. 3
Keynote Speakers	p. 4
Lifetime Achievement Award	p. 6
Program at a glance	p. 7
– Wednesday, October 24	p. 9
– Thursday, October 25	p. 10
– Friday, October 26	p. 14
– Saturday, October 27	p. 18
Poster presentations	p. 21
Theme 1. Clinical trials: Methodology	p. 22-24
Theme 2. Clinical trials: Results	p. 25-27
Theme 3. Clinical trials: Imaging	p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma	p. 30-34
Theme 5. Clinical trials: Cognitive and functional endpoints	p. 35-38
Theme 6. Cognitive assessment and clinical trials	p. 39-42
Theme 7. Behavioral disorders and clinical trials	p. 43
Theme 8. Health economics and clinical trials	p. 44
Theme 9. Epidemiology and clinical trials	p. 45-46
Theme 10. Clinical Trials: Animal Models	p. 47
Theme 11. New therapies and clinical trials	p. 48-49
Privileged partners	p. 50
General information	p. 51



Clinical Trials on Alzheimer's Disease

CTAD Organizing Committee

Jacques Touchon MD, PhD
University
Hospital of Montpellier
France

Paul Aisen MD
Alzheimer's
Therapeutic Research Institute (ATRI)
University of Southern California (USC),
San Diego, USA

Bruno Vellas MD, PhD
University
Hospital of Toulouse
France

Mike Weiner MD
University of California
San Francisco (UCSF)
USA

CTAD Scientific Committee


Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Steven DEKOSKY (Miami)
Rachelle DOODY (Basel)
Bruno DUBOIS (Paris)
Howard FELDMAN (San Diego)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GIACOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)

Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesota)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Rachel SCHINDLER (New York)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov STERN (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)



Clinical Trials on Alzheimer's Disease

KEYNOTE SKEAKERS



«Blood biomarkers for AD clinical trials»

Randall Bateman, MD, PhD

Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer's disease. Dr. Bateman's laboratory investigates the causes and future diagnosis and treatments of Alzheimer's disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer's disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer's Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.



«What have we learned from Aducanumab?»

Samantha Budd Haeberlein, PhD

Vice President of Alzheimer's Disease Discovery & Development, Biogen, Boston, USA

Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer's Disease Discovery & Development. Dr. Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr. Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women's Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.



«Anti-Tau Treatments: Potential, Challenges, and Progress»

Lennart Mucke, MD

Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Dr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco. He trained at the Free University Berlin, the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Göttingen, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School, and The Scripps Research Institute. Dr. Mucke's research focuses on mechanisms that result in functional deficits in Alzheimer's disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Mucke has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer's Association and on the National Advisory Council on Aging for the NIH.



Clinical Trials on Alzheimer's Disease

KEYNOTE SKEAKERS



«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD

Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor Joao Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008-2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010-2014.



«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD

Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky, serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Scientifics, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer's disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.



*2018 Recipient of the CTAD
Lifetime Achievement Award*

Rachelle Doody MD, PhD

Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and its US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer's Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer's Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer's Disease Cooperative Study (ADCS) and Alzheimer's Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer's Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.

Wednesday, October 24

4.00 - 4.30 p.m.

Opening Ceremony and CTAD Lifetime Achievement Award

4.30 - 5.00 p.m.

Keynote 1 - Blood biomarkers for AD clinical trials

5.00 - 5.50 p.m.

Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer's disease

5.50 - 6.40 p.m.

**Emerging Results From Other BACE Inhibitor Trials
Discussion of BACEi Trial Findings: Challenges and Opportunities**

6.40 - 7.00 p.m.

Late breaking oral communication

Thursday, October 25

8.30 - 10.00 a.m.

Oral communications

10.00 - 10.30 a.m.

Coffee break and poster session

10.30 - 11.30 a.m.

Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer's disease?

11.30 - 12.30 p.m.

Oral communications

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.00 p.m.

Keynote 2 - What have we learned from Aducanumab?

2.00 - 2.30 p.m.

Late breaking oral communications

2.30 - 3.30 p.m.

Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

3.30 - 4.30 p.m.

Oral communications

4.30 - 5.00 p.m.

Coffee break and poster session

5.00 - 6.00 p.m.

Symposium 4 - A β blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer's disease.

Friday, October 26

8.30 - 10.00 a.m.

Oral communications

10.00 - 10.30 a.m.

Coffee break and poster session

10.30 - 11.00 a.m.

Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress

11.00 - 11.30 p.m.

Late Breaking communications

11.30 - 12.30 p.m.

Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer's Disease (AD)

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.45 p.m.

Oral communications

2.45 - 4.00 p.m.

Late Breaking communications

4.00 - 4.30 p.m.

Coffee break and poster session

4.30 - 5.00 p.m.

Keynote 4 - Combination therapy in AD

5.00 - 6.00 p.m.

Symposium 6 - Endpoints for early Alzheimer's disease clinical trials: Interpretation and application of the draft FDA guidance

Saturday, October 27

8.30 - 9.15 a.m.

Presentation and panel discussion: AMBAR (Alzheimer's Management By Albumin Replacement) Phase IIb/III Results

9.15 - 9.45 a.m.

Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research

9.45 - 10.15 a.m.

Coffee break and poster session

10.15 - 11.15 a.m.

Oral communications

11.15 - 12.15 p.m.

Symposium 7 - Disclosure of Alzheimer's risk biomarkers to cognitively normal older adults

12.15 - 1.15 p.m.

Lunch and poster session

1.15 - 3.45 p.m.

Oral communications

3.45 p.m.

End of conference

Wednesday, October 24

4.00 - 4.30 p.m.

Opening Ceremony and CTAD Lifetime Achievement Award

Jacques Touchon, Paul Aisen, Bruno Vellas, Mike Weiner, Merce Boada, Jose Luis Molinuevo. The recipient of this year's CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials

4.30 - 5.00 p.m.

Keynote 1

Blood biomarkers for AD clinical trials

Introduction by: Bruno Vellas, MD, PhD

Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

5.00 - 5.50 p.m.

Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer's disease

Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

Communication 1: Results from the APECS trial

Michael F. Egan, MD¹, Tiffini Voss, MD¹, Yuki Mukai, MD¹, James Kost, PhD¹, Paul S Aisen, MD², Jeffrey L. Cummings, MD, ScD³, Pierre N. Tariot, MD⁴, Bruno Vellas, MD, PhD⁵, Christopher H. van Dycck, MD⁶, Ying Zhang, PhD¹, Wen Li, PhD¹, Christine Furtek, BS¹, Erin Mahoney, BA¹, Lyn Harper Mozley, PhD¹, Yi Mo, PhD¹, Cyrille Sur, PhD¹, David Michelson, MD¹

¹Merck & Co., Inc., Kenilworth, NJ, USA ²University of Southern California, San Diego, CA, USA ³Cleveland Clinic, Las Vegas, NV, USA ⁴Banner Alzheimer's Institute, Phoenix, AZ, USA ⁵Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France ⁶Yale University School of Medicine, New Haven, CT, USA

Communication 2: Panel discussion

Paul S. Aisen, MD¹, Maria C. Carrillo, PhD², Pierre N. Tariot, MD³, Bruno Vellas, MD, PhD⁴

¹University of Southern California, San Diego, CA, USA ²The Alzheimer Association, Chicago, IL, USA ³Banner Alzheimer's Institute, Phoenix, AZ, USA ⁴Gerontopole, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France

5.50 - 6.40 p.m.

Emerging Results From Other BACE Inhibitor Trials Discussion of BACEi Trial Findings: Challenges and Opportunities

CoChairs: Reisa Sperling, MD, Brigham & Women's Hospital, Maria C. Carrillo, PhD, Alzheimer's Association

Presentation 1: Preliminary analyses of data from an ongoing trial of atabecestat in preclinical Alzheimer's disease. Gary Romano, MD, PhD Janssen R&D, USA

Presentation 2: LBI - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer's disease dementia.

Albert C Lo¹, Cynthia Duggan Evans¹, Michele Mancini¹, Qun Lin, Hong Wang¹, Peng Liu¹, Sergey Shcherbinin¹, Ming Lu², Arnaud Charil¹, Brian A Willis¹, Michael Irizarry³

¹Eli Lilly and Company, Indianapolis, IN, USA, ²Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, USA, ³Eli Lilly and Company, Indianapolis IN, USA; now at Eisai Inc, Woodcliff Lake, NJ

Panel discussion: Reisa Sperling, MD, Brigham & Women's Hospital, Maria C. Carrillo, PhD, Alzheimer's Association, Mark Mintun, MD, Eli Lilly & Co., Michael Egan, MD, Merck & Co., Gary Romano, MD, PhD Janssen R&D, Ana Graf, MD, Novartis & Amgen, Inc., Johan Luthman, MD, Eisai Co., Ltd., John Sims, MD, Lilly/AZ Alliance

6.40 - 7.00 p.m.

Late Breaking Oral communication

Chair: Maria Carrillo, PhD

6.40 - 7.00 p.m.

LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results

Robert Alexander, MD¹, Daniel K. Burns, PhD², Kathleen A. Welsh-Bohmer, PhD³, Carl Chiang, PhD², Meredith Culp, BS⁴, Janet O'Neil, MBA⁴, Brenda L. Plassman, PhD³, Craig Metz, PhD², Deborah Yarbrough, MS, MBA⁴, Jingtao Wu, PhD¹, Rebecca Evans, MD¹, Kumar Budur, MD⁴, Stephen K. Brannan, MD⁴, Ann M. Saunders, PhD², Emiliangelo Ratti, PhD¹; for the TOMMORROW Study Investigators

¹Takeda Development Center Americas, Inc., Cambridge, MA, USA, ²Zinfandel Pharmaceuticals, Inc., Durham, NC, USA, ³Duke University Bryan ADRC, Durham, NC, USA, ⁴Takeda Development Center Americas, Inc., Deerfield, IL, USA



Thursday, October 25

8.30 - 10.00 a.m.

Oral communications

Chairs: Suzanne Craft, MD, PhD and Rachel Schindler, PhD

8.30 - 8.45 a.m. OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer's dementia

Christopher H. van Dyck, MD¹, Haakon B. Nygaard, MD, PhD², Kewei Chen, PhD³, Michael C. Donohue, PhD⁴, Rema Raman, PhD⁴, Robert A. Rissman, PhD^{4,5}, James B. Brewer, MD, PhD⁵, Robert A. Koeppe, PhD⁶, Tiffany W. Chow, MD⁴, Michael S. Rafii, MD⁴, R. Scott Turner, MD, PhD⁷, Jeffrey A. Kaye, MD⁸, Seth A. Gale, MD⁹, Eric M. Reiman, MD³, Paul S. Aisen, MD⁴, Stephen M. Strittmatter, MD, PhD¹

¹Yale University School of Medicine, New Haven, USA ²The University of British Columbia, Vancouver, Canada ³Banner Alzheimer's Institute, Phoenix, USA ⁴Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA ⁵University of California San Diego, La Jolla, USA ⁶University of Michigan, Ann Arbor, USA ⁷Georgetown University, Washington, DC, USA ⁸Oregon Health & Science University, Portland, USA ⁹Harvard Medical School, Boston, USA

8.45 - 9.00 a.m. OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics

Suzanne Craft, PhD¹, Rema Raman, PhD², Tiffany Chow, MD², Michael S Rafii, MD², Robert A. Rissman, PhD³, James B. Brewer, MD³, Michael Donohue, PhD², Chung-Kai Sun, MS², Kelly Harless², Devon Gessert², Paul S. Aisen, MD²

¹Wake Forest School of Medicine, Winston-Salem, USA, ²University of Southern California, Los Angeles, USA, ³University of California, San Diego, USA

9.00 - 9.15 a.m. OC3 - Phase3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China

Shifu Xiao, MD¹, Zhenxin Zhang, MD², Meiyu Geng, PhD³, GV-971 Study Group

¹Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China ²Peking Union Medical College Hospital, Beijing, China ³State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m. OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study

Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team

United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m. OC5 - Elenbecestat in MCI-to-moderate Alzheimer's disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints

Shau Yu Lynch, PhD¹, June Kaplow, PhD¹, Jim Zhao, MS, MM¹, Shobha Dhadda, PhD¹, Johan Luthman, PhD, DDS¹, Bruce Albala, PhD¹

¹Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m. OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer's disease: Phase Ib/2a outcomes update

Roberta D. Brinton, PhD¹, Gerson D. Hernandez, MD, MPH¹, Naoko Kono, MPH², Claudia M. Lopez, BS¹, Christine Solinsky, PhD³, Kathleen Rodgers, PhD¹, Jin Gahm, PhD⁴, Dogu Aydogan, PhD⁴, Yonggang Shi, PhD⁴, Sonia Pawluczuk, MD⁵, Meng Law, MD⁶, Wendy Mack, PhD², Lon Schneider, MD, MS⁵

¹Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA ²Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA ³School of Pharmacy, University of Southern California, Los Angeles, CA, USA ⁴USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA ⁵Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA ⁶Department of Radiology, University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m.

Coffee break and poster session



Thursday, October 25

10.30 - 11.30 a.m.

Symposium 2

Is BACE1 a suitable drug target for prevention and treatment of Alzheimer's disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers ?

Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.

Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.

Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc., NJ, USA

11.30 - 12.30 p.m.

Oral communications

Chair: Lon Schneider, MD

11.30 - 11.45 a.m.

OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study

Gil D. Rabinovici¹, Constantine Gatsonis,² Charles Apgar,³ Kiran Chaudhary,¹ Ilana Gareen,² Lucy Hanna,² James Hendrix,⁴ Bruce E. Hillner,⁵ Cynthia Olson,³ Orit Lesman-Segev,¹ Justin Romanoff,² Barry A. Siegel,⁶ Rachel A. Whitmer,⁷ Maria C. Carrillo,⁴ on behalf of the IDEAS investigators.

¹Department of Neurology, University of California San Francisco, ²Center for Statistical Sciences, Brown University, ³American College of Radiology, ⁴Alzheimer's Association, ⁵Department of Medicine, Virginia Commonwealth University, ⁶Department of Radiology, Washington University, ⁷Division of Research, Kaiser Permanente

11.45 - 12.00 p.m.

OC8 - Safety and efficacy of estrogen receptor- β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase 1b/2a trial outcomes

Lon S. Schneider, MD¹, Gerson Hernandez MD MPH², Liqin Zhao PhD³, Sonia Pawluczyk MD,¹ Wendy J. Mack, PhD¹, Roberta D. Brinton PhD²

¹Keck School of Medicine of the University of Southern California, Los Angeles, USA, ²University of Arizona, Center for Innovation in Brain Science, Tucson, USA, ³University of Kansas, USA

12.00 - 12.15 p.m.

OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD

Huntington Potter, PhD Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels

Rocky Mountain Alzheimer's Disease Center, Department of Neurology University of Colorado School of Medicine

12.15 - 12.30 p.m.

OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer's disease

David Allsop PhD^{1,2}, Anthony Aggidis MSc¹, Nigel Fullwood PhD¹, Mark Taylor PhD^{1,2}, Penny Foulds PhD^{1,2}, Shoona Vincent PhD², Mark Dale MD²

¹Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, ²Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.00 p.m.

Keynote 2

What have we learned from Aducanumab?

Introduction: Jacques Touchon, MD, PhD

Samantha Budd Haerberlein, PhD - Vice President of Alzheimer's Disease Discovery & Development, Biogen, Boston, USA



Thursday, October 25

2.00 - 2.30 p.m.

Late Breaking Oral communications

Chair: Reisa Sperling, MD, PhD

2.00 - 2.15 p.m.

LB3 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer's disease

Bjørn Sperling, MD¹, Lars Østergaard Pedersen, PhD¹, Neli Boneva, MD¹, Dorthe Daugaard, MD¹, Yudong Zhao, PhD¹

¹H. Lundbeck A/S, Valby, Denmark

2.15 - 2.30 p.m.

LB4 - Predictors of [18F]flortaucipir (tau) load in Alzheimer's disease and other neurodegenerative disorders

Oskar Hansson, MD, PhD^{1,2}, Gil D. Rabinovici MD, PhD³, Chul H. Lyoo, MD, PhD⁴ & Rik Ossenkoppele, PhD^{1,5}

¹Lund University, Clinical Memory Research Unit, Lund, Sweden, ²Memory Clinic, Skåne University Hospital, Malmö, Sweden, ³Department of Neurology, University of California San Francisco, San Francisco, USA, ⁴Memory and Aging Center, ⁵Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁵VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

2.30 - 3.30 p.m.

Symposium 3

Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

Communication 1: BAN2401 Study 201 Study Design and Topline Results

Jeffrey L. Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Communication 2: Pre-specified Subgroup Analysis in BAN2401 Study 201

Chad J. Swanson, PhD, Eisai Inc.

Communication 3: Effect of BAN2401 on Underlying AD Pathophysiology

Chad J. Swanson, PhD, Eisai Inc.

Communication 4: Totality of Results from BAN2401 Study 201

Jeffrey L. Cummings, MD, ScD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Q&A followed by a panel discussion: Jeffrey L. Cummings, MD, ScD, Chad J. Swanson, PhD, Akihito Koyama, PhD, Eisai Inc.

3.30 - 4.30 p.m.

Oral communications

Chair: Michael Egan, MD

3.30 - 3.45 p.m.

OC11 - Safety and efficacy of lemborexant for sleep-wake regulation in patients with irregular sleep wake rhythm disorder and Alzheimer's disease dementia

Margaret Moline, PhD¹, Mohammad Bsharat, PhD¹, Manuel Kemethofer, MSc², Gleb Filippov, MD, PhD¹, Naoki Kubota, MPharm³, Patricia Murphy, PhD¹

¹Eisai, Inc., Woodcliff Lake, USA, ²The Siesta Group, Vienna, Austria, ³Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m.

OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies

Adam S Fleisher², Michael J Pontecorvo², Michael D Devous², Ming Lu², Sergey Shcherbinin¹, Anupa K Arora², Mark A Mintun^{1,2}.

¹Eli Lilly & Co, Indianapolis, IN, USA, ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00 - 4.15 p.m.

OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer's disease

Cyrille Sur, PhD¹, James Kost, PhD¹, David Scott, PhD², Katarzyna Adamczuk, PhD², Nick C Fox, PhD³, Jeffrey Cummings, MD, ScD⁴, Pierre Tariot, MD⁵, Paul Aisen, MD⁶, Bruno Vellas, MD, PhD⁷, Tiffini Voss, MD¹, Yuki Mukai, MD¹, David Michelson, MD¹, Michael Egan, MD¹

¹Merck & Co., Inc., Kenilworth, NJ, USA, ²Bioclinica, Newark, CA, USA, ³University College London, London, UK, ⁴Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ⁵Banner Alzheimer's Institute, Phoenix, AZ, USA, ⁶University of California San Diego, San Diego, CA, USA, ⁷Gerontopole, Toulouse University Hospital, Toulouse, France



Thursday, October 25

4.15- 4.30 p.m.

OCI4 - Distinct Tau PET Patterns in Atrophy-Defined Subtypes of Alzheimer's disease

Rik Ossenkoppele, Ph.D.^{1,2}, Gil D. Rabinovici, M.D.³, Chul H. Lyoo, M.D., Ph.D.⁴ & Oskar Hansson, M.D., Ph.D.^{1,5}

¹Lund University, Clinical Memory Research Unit, Lund, Sweden, ²VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, ³Department of Neurology, University of California San Francisco, San Francisco, USA, Memory and Aging Center, ⁴Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ⁵Memory Clinic, Skåne University Hospital, Malmö, Sweden.

4.30 - 5.00 p.m.

Coffee break and poster session

5.00 - 6.00 p.m.

Symposium 4

A β blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer's disease.

Moderator : Pedro Pesini PhD. Araclon Biotech-Grifols, Spain.

Communication 1: Developing A β blood based test into pre- screening tools for clinical trials in early stages of AD
Victor L. Villemagne, M.D. Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

Communication 2: Plasma ratio of total A β 42 to total A β 40 in amnesic MCI patients is associated with FDG-PET, amyloid- PET, CSF and the risk of progression to AD dementia.
Anne Fagan PhD, Washington University, Saint Louis, Missouri.

Communication 3: Total A β 42 to total A β 40 as a biomarker of cortical amyloid burden in subjects with subjective memory complaints.

Agustín Ruiz MD PhD. Research Director, Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya (UIC), Barcelona, Spain.



Friday, October 26

8.30 - 10.00 a.m.

Oral communications

Chairs: Laura D. Baker, PhD and Ana Graf, MD

8.30 - 8.45 a.m.

OC15 - Cocoa supplement and multivitamin outcomes study of cognitive function (cosmos-mind): design of a large randomized clinical trial

[Laura D. Baker](#), PhD¹, Mark A. Espeland, PhD¹, Stephen R. Rapp, PhD¹, Sally A. Shumaker, PhD¹, Sarah A. Gaussoin, MS¹, Howard D. Sesso, ScD², JoAnn E. Manson, MD, DrPH²

¹Wake Forest School of Medicine, Winston-Salem, USA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, USA

8.45 - 9.00 a.m.

OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer's disease

[Jonas Hannestad](#), MD PhD¹, Ian Gallager, PhD¹, Katie Koborsi, MS¹, S. Sakura Minami, PhD¹, Darby Stephens, MBA¹, Viktoria Kheifets, PhD¹, Steven Braithwaite, PhD¹

¹Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m.

OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer's disease patients in general population

[Olga Uspenskaya-Cadoz](#)¹, Chaitanya Alamuri², Sam Khinda³, Yuliya Nigmatullina², Carolina Rubel³, Lanhui Wang², Mengting Yang², Tao Cao², Nikhil Kayal²

¹IQVIA CNS Center of Excellence, ²IQVIA Analytics Center of Excellence, ³IQVIA Project Leadership

9.15 - 9.30 a.m.

OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer's disease: Updated design and baseline characteristics of phase 2 study

Hana Florian, MD¹, Steven E. Arnold, MD², Randall J. Bateman, MD³, Joel B. Braunstein, MD, MBA⁴, [Kumar Budur](#), MD¹, Diana R. Kerwin, MD⁵, Holly Soares, PhD¹, Deli Wang, PhD¹, David M. Holtzman, MD³

¹AbbVie, Inc., North Chicago, IL, USA, ²Massachusetts General Hospital, Boston, MA, USA, ³Washington University, St. Louis, MO, USA, ⁴C_N Diagnostics LLC, St. Louis, MO, USA, ⁵Texas Health Presbyterian Hospital, Dallas, TX, USA

9.30 - 9.45 a.m.

OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in real life (IMAP) study

[A. Graf](#)¹, V. Risson¹, S. Tziveleki², A. Gustavsson³, V. Bezlyak¹, A. Caputo¹, P.N. Tariot⁴, J.B. Langbaum⁴, C. Lopez Lopez¹, V. Viglietta²

¹Novartis Pharma AG, ²Amgen, Inc., ³Quantify Research, ⁴Banner Alzheimer's Institute

9.45 - 10.00 a.m.

OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer's disease to four large study cohorts.

[Roos J. Jutten](#), MSc¹, Rebecca E. Amariglio, PhD^{2,3}, Gad A. Marshall, MD, PhD^{2,3}, Dorene M. Rentz, PhD^{2,3}, Wiesje M. Van der Flier, PhD¹, Philip Scheltens, MD, PhD¹, Keith A. Johnson^{2,4}, Reisa A. Sperling, MD^{2,3}, PhD, Sietske A.M. Sirkes, PhD³, Kathryn V. Papp, PhD^{2,3}

¹Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, ²Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA, ³Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA, ⁴Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

10.00 - 10.30 a.m.

Coffee break and poster session

10.30 - 11.00 a.m.

Keynote 3

Anti-Tau treatments: Potential, challenges, and progress

Introduction: Paul Aisen, MD

Lennart Mucke, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA



Friday, October 26

11.00 - 11.30 p.m.

Late Breaking communication and panel discussion

11.00 - 11.30 a.m.

LB5 - 18F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology

Mark A. Mintun^{1,2}, Adam S. Fleisher², Michael D. Devous², Ming Lu², Anupa K. Arora², Thomas G. Beach³, Thomas J. Montine⁴, Michael J. Pontecorvo²

¹Eli Lilly and Company, Indianapolis, IN, USA, ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA, ³Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA, ⁴Department of Pathology, Stanford University, Stanford, CA, USA

11.30 - 12.30 p.m.

Symposium 5

Towards the Development of a Complete Solution for Patients with Alzheimer's Disease (AD)

Moderator: Rachele Doody, MD, PhD^{1,2}

¹Genentech, Inc., South San Francisco, CA, USA, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland

Communication 1: Self-detection of cognitive problems: benefits and challenges of online and digital tools

Mary Sano, PhD^{1,2}

¹Director, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Communication 2: Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers

Christopher van Dyck, MD¹⁻⁴

¹Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA, ²Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA, ³Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA, ⁴Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

Communication 3: Moving towards combination therapies for disease modification in AD

Dennis J. Selkoe, MD^{1,2}

¹Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA, ²Harvard Medical School, Boston, MA, USA

12.30 - 1.30 p.m.

Lunch and poster session

1.30 - 2.45 p.m.

Oral communications

Chairs: Sandrine Andrieu, MD, PhD and Gregory Klein, PhD

1.30 - 1.45 p.m.

OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures

Lyduine Collij, MSc,¹ Fiona Heeman, MSc,¹ Gemma Salvadó Blasco, MSc,² Elles Konijnenberg, MD, MSc,³ Anouk den Braber, PhD,⁴ Maqsood Yaqub, PhD,¹ Pieter Jelle Visser, MD, PhD,³ Alle Meije Wink, Ir, PhD,¹ Philip Scheltens, MD, PhD,³ Ronald Boellaard, PhD,¹ Bart N.M. van Berckel, MD, PhD,¹ Juan Domingo Gisbert López, PhD,² Mark Schmidt, MD, PhD,⁵ Frederik Barkhof, MD, PhD,^{1,6} Isadora Lopes Alves, PhD,¹

¹Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, ²BarcelonaBeta Brain Research Center, Barcelona, Spain, ³Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands, ⁴Dept. of Biological Psychology, VU University Amsterdam, The Netherlands, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom.

1.45 - 2.00 p.m.

OC22 - Twenty-four-month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies

Gregory Klein, PhD¹, Paul Delmar, PhD², Carsten Hofmann, PhD¹, Danielle Abi-Saab, PsyD², Mirjana Andjelkovic, PhD², Smiljana Ristic, MD², Nicola Voyle, PhD³, Jacob Hesterman, PhD⁴, John Seibyl⁴, Ken Marek⁴, Ferenc Martenyi, MD², Monika Baudler, PhD², Paulo Fontoura, MD, PhD², Rachele Doody, MD, PhD²

¹Roche Pharma Research and Early Development, Basel, Switzerland, ²Roche / Genentech Product Development, Neuroscience, Basel, Switzerland, ³Roche Products Ltd, Welwyn Garden City, UK, ⁴InviCRO, LLC, Boston, MA, US

Friday, October 26

- 2.00 - 2.15 p.m.** **OC23 - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS**
Miia Kivipelto^{1,2,3}, On behalf of the World-Wide FINGERS network
¹Karolinska Institutet, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden, ²University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland, ³Imperial College London, NEA, School of Public Health, UK
- 2.15 - 2.30 p.m.** **OC24 - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials**
Christian Dansereau^{1,2}, PhD, Maor Zaltzhendler¹, MEng, Angela Tam^{2,3}, MSc, Pedro Rosa-Neto³, MD, PhD, Serge Gauthier³, MD, Pierre Bellec^{2,4}, PhD
¹Perceiv Research Inc., Montreal, CAN, ²Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, CAN, ³Douglas Mental Health University Institute, McGill University, CAN, ⁴Department of Computer Science and Operations Research, University of Montreal, CAN
- 2.30 - 2.45 p.m.** **OC25 - Study update on XanADu: Phase II study of Xanamem™ in subjects with mild dementia due to Alzheimer's disease**
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

2.45 - 4.00 p.m.

Late Breaking communications

Chairs: Pierre-Jean Ousset, MD and Marwan Sabbagh MD

- 2.45 - 3.00 p.m.** **LB6 - Age and ApoE genotype-specific population frequencies of cerebral β -amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO**
Hany Rofael, MD, PhD¹, Gerald Novak MD¹, Luc Bracoud MSc², Nandini Raghavan PhD¹, Ziad Saad PhD³, S Einstein MS¹, Robert Brashear¹, David Scott PhD⁴, Joel Schaerer PhD², Celeste de Jager PhD⁵, Chi Udeh-Momoh, PhD⁵, the Alzheimer's Disease Neuroimaging Initiative (ADNI), and Lefkos Middleton MD⁵
- 3.00 - 3.15 p.m.** **LB7 - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer's disease**
Marwan Sabbagh, MD¹, Imogene Dunn, PhD², Ann Gooch, PhD², Tom Soeder, MS³, Karl Kiebertz, MD, MPH⁴, Carmen Valcarce, PhD², Larry D Altstiel, MD, PhD^{2*}, Aaron H Burstein, PharmD²
¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ²vTv Therapeutics LLC, High Point, NC, USA, ³Cato Research LTD, Durham, NC, USA, ⁴Clintrex LLC, Longboat Key, FL, USA
- 3.15 - 3.30 p.m.** **LB8 - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer's disease**
Samantha Budd Haeberlein, PhD¹, Carmen Castrillo-Viguera, MD¹, Tianle Chen, PhD¹, John O'Gorman, PhD¹, Raj Rajagovindan, PhD¹, Dakshaben Patel, PhD², Philipp von Rosenstiel, MD¹, Guanfang Wang, PhD³, Spyros Chalkias, MD¹, LeAnne Skordos PharmD¹, Claudia Prada, MD¹, Christoph Hock, MD⁴, Roger M Nitsch, MD⁴, Alfred Sandrock, MD, PhD¹
¹Biogen, Cambridge, MA, USA, ²Biogen, Maidenhead, UK, ³Cytel, Cambridge, MA, USA, ⁴Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland
- 3.30 - 3.45 p.m.** **LB9 - Longitudinal 148-Week Extension Study for ANAVEX®-2-73 Phase 2a Alzheimer's Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers**
Harald Hampel, MD, PhD¹, Mohammad Afshar, MD, PhD², Frédéric Parmentier, PhD², Coralie Williams, MSc², Adrien Etcheto, MSc², Federico Goodsaid, PhD³, Christopher U Missling, PhD⁴
¹Department of Neurology, Sorbonne University, Paris, France, ²Ariana Pharma, Paris, France, ³Regulatory Pathfinders LLC, San Francisco, CA, ⁴Anavex Life Sciences Corp., New York, NY
- 3.45 - 4.00 p.m.** **LB10 - Predictive performance of CSF and imaging AD biomarkers in ADNI/GO/2 MCI participants using the NIA-AA research framework**
Leslie M Shaw, PhD¹, Michal Figurski, PhD¹, Susan Landau, PhD², William Jagust, MD², Clifford R Jack, MD³, Paul S Aisen, MD⁴, Ronald C Petersen, MD³, Michael W Weiner, MD⁵, John Q Trojanowski, MD, PhD¹
¹University of Pennsylvania, Philadelphia, USA, ²University of California, Berkeley, Berkeley, USA, ³Mayo Clinic, Rochester, USA, ⁴University of Southern California, San Diego, USA, ⁵University of California, San Francisco, San Francisco, USA



Friday, October 26

4.00 - 4.30 p.m.

Coffee break and poster session

4.30 - 5.00 p.m.

Keynote 4

Combination therapy in AD

Introduction: Jeffrey Cummings, MD, PhD

Daniel M. Skovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m.

Symposium 6

Endpoints for early Alzheimer's disease clinical trials: Interpretation and application of the draft FDA guidance

Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA

Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease

Reisa Sperling, MD¹, Ronald C. Petersen, MD, PhD², Gary Romano, MD, PhD³, Paul Maruff, PhD⁴

¹Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA, ²Department of Neurology, Mayo Clinic, Rochester, MN, USA, ³Janssen R&D, Titusville, NJ, USA, ⁴Cogstate Ltd, Melbourne, Victoria, Australia

Communication 2: Biomarkers in Stage 1, 2 and 3 Disease

Samantha Budd Haerberlein PhD¹, Jose Luis Molinuevo, MD, PhD², Christopher C. Rowe, PhD³, Maria C. Carrillo PhD⁴, Clifford R. Jack, Jr., MD⁵

¹Biogen, Cambridge, MA, USA, ²BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain, ³Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, ⁴Alzheimer's Association, Chicago, IL, USA, ⁵Department of Radiology, Mayo Clinic, Rochester, MN, USA

Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects

Chris J. Edgar, PhD¹, George Vradenburg, JD², Jason Hassenstab, PhD³

¹Cogstate Ltd, London, UK, ²UsAgainstAlzheimer's and Alzheimer's Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, ³Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA



Saturday, October 27

8.30 - 9.15 a.m.

Presentation and panel discussion: AMBAR (Alzheimer's Management By Albumin Replacement) Phase IIb/III Results

Presentation by Antonio Páez MD, Grifols S.A., Barcelona, Spain

Followed by Panel Discussion with:

Panel discussion moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m.

Keynote 5 How BIG and GOOD Data are revolutionizing neurodegenerative disease research

Introduction: Bruno Vellas, MD, PhD

Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA

9.45 - 10.15 a.m.

Coffee break and poster session

10.15 - 11.15 a.m.

Oral communications

Merce Boada, MD, PhD and Jacques Touchon, MD, PhD

10.15 - 10.30 a.m.

OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials
Tharick A. Pascoal MD¹, Sulantha Mathotaarachchi MSc¹, Mira Chamoun PhD², Joseph Therriault BSc¹, Robert Hopewell PhD², Gassan Massarweh PhD², Andrea L. Benedet¹, MSc, BSc, Min Su Kang¹, Jean-Paul Soucy MD¹, Serge Gauthier¹, MD, Pedro Rosa-Neto¹, MD, PhD

¹Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada,

²Montreal Neurological Institute, McGill University, Montreal, Canada

10.30 - 10.45 a.m.

OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer's disease in AIBL

Samantha C. Burnham^{1,2}, Preciosa M Coloma³, Qiao-Xing Li⁴, Steven Collins⁵, Greg Savage⁶, Simon Laws², James Doecke⁷, Paul Maruff⁸, Ralph N Martins^{2,9}, David Ames¹⁰, Christopher C Rowe¹¹, Colin L Masters⁴, Victor L Villemagne^{4,11}

¹eHealth, CSIRO, Parkville, VIC, Australia, ²School of Medical Sciences, Edith Cowan University, Joondalup, Australia, ³Product Development Personalised Health Care - Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia, ⁵Department of Pathology, University of Melbourne, Parkville, Australia, ⁶Macquarie University, Sydney, Australia, ⁷eHealth, CSIRO, Herston, QLD, Australia, ⁸Cogstate Ltd, Melbourne, Australia, ⁹Macquarie University, North Ryde, Australia, ¹⁰National Ageing Research Institute, Melbourne, Australia, ¹¹Austin Health, Melbourne, Australia Brain Health, Las Vegas, NV, USA

10.45 - 11.00 a.m.

OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis

Jacques Touchon, MD, PhD^{1,2}, Laura Auboyer, PhD³, Johann Meunier, PhD⁴, Laura Ceolin, PhD⁴, François J. Roman, PhD⁴, Rémy Burcelin, PhD⁵, Guillaume J. Blivet, MS³

¹Montpellier University, France, ²INSERM U1061, Montpellier, France, ³REGENLIFE SAS, Montpellier, France, ⁴Amylgen SAS, Montferrier-sur-Lez, France, ⁵Vaiomer SAS, Labège, France



Saturday, October 27

11.00 - 11.15 a.m.

OC29 - Elecsys® CSF biomarker immunoassays demonstrate concordance with results of Amyloid-PET imaging in AIBL patient samples

Larry Ward, PhD¹, Samantha C. Burnham, PhD^{4,7}, Victor L. Villemagne MD^{5,6}, Qiao-Xin Li, PhD⁵, Steven Collins MBBS PhD⁵, Christopher J Fowler PhD⁵, Ekaterina Manuilova, PhD², Monika Widmann, ChTech³, Stephanie Rainey-Smith PhD⁷, Colin L Masters MD⁵, James D Doecke, PhD^{1,8}

¹Cooperative Research Council for Mental Health, Melbourne, Vic, Australia, ²Roche Diagnostics GmbH, Penzberg, Germany, ³Roche Diagnostics GmbH, Mannheim, Germany, ⁴Commonwealth Scientific Industry and Research Organisation/Australian E- Health Research Centre, Parkville, Melbourne, QLD, Australia, ⁵The Florey Institute, The University of Melbourne, Parkville, Australia, ⁶Austin Health, Department of Molecular Imaging and Therapy, Center for PET, Heidelberg, Victoria, Australia, ⁷School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁸Commonwealth Scientific Industry and Research Organisation/Australian E- Health Research Centre, Brisbane, QLD, Australia

11.15 - 12.15 p.m.

Symposium 7

Disclosure of Alzheimer's risk biomarkers to cognitively normal older adults

Symposium co-moderators: Athene Lee PhD^{1,2} and Jessica Alber PhD^{1,2}

¹Warren Alpert Medical School of Brown University, Providence, RI, USA ²Butler Hospital, Providence, RI, USA

Communication 1: "Not just a colonoscopy" – cognitively normal older adults reactions to learning an amyloid PET result

Jason Karlawish, MD¹, Kristin Harkins, MPH², Emily Largent, JD, PhD³, Pamela Sankar, PhD³, Jeff Burns, MD⁴, David Sulzer, MD⁵, Joshua Grill, PhD⁶

¹Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA, ²Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA, ³Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA, ⁴Department of Neurology, University of Kansas, Kansas City, KS, USA, ⁵Department of Psychiatry, University of California, Los Angeles, CA, USA, ⁶Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

Communication 2: Remote genetic counseling and disclosure of APOE genotype within the Generation study I

Elisabeth McCarty Wood, MS¹, Cara Cacioppo, MS¹, Neeraja Reddy, MS², Dare Henry-Moss, MPH¹, Demetrios Ofidis, BS¹, Brian L. Egleston, PhD³, Jason Karlawish, MD¹, J Scott Roberts, PhD⁴, Scott Kim, MD, PhD⁵, Carolyn Langlois, MA⁶, Eric M. Reiman, MD⁶, Pierre N. Tariot, MD⁶, Jessica B. Langbaum, PhD⁶, Angela R. Bradbury, MD¹

¹University of Pennsylvania, Philadelphia, PA, USA, ²Mapmygenome, Navi Mumbai, India, ³Fox Chase Cancer Center, Philadelphia, PA, USA, ⁴University of Michigan, Ann Arbor, MI, USA, ⁵National Institutes of Health, Bethesda, MD, USA, ⁶Banner Alzheimer's Institute, Phoenix, AZ, USA

Communication 3: Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results

Louisa Thompson, PhD^{1,2}, Athene Lee, PhD^{1,2}, Meghan Collier, PhD^{1,2}, Danielle Goldfarb, MD¹, Brittany Dawson, FNP², Stephen Salloway, MD^{1,2}, Jessica Alber, PhD^{1,2}

¹Warren Alpert Medical School of Brown University, Providence, RI, USA, ²Butler Hospital, Providence, RI, USA

12.15 - 1.15 p.m.

Lunch and poster session

1.15 - 3.45 p.m.

Oral communications

Gustavo A. Jimenez-Maggiara and Suzanne Hendrix, PhD

1.15 - 1.30 p.m.

OC30 - Adult conditional BACE1 knockout mice exhibit axonal organization defects in the hippocampus

Robert Vassar, PhD Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

1.30 - 1.45 p.m.

OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation

Gustavo A. Jimenez-Maggiara, MBA¹, Rema Raman, PhD¹, Michael S. Rafii, MD, PhD¹, Reisa Anne Sperling, MD^{2,3}, Jeffrey Lee Cummings, MD⁴, Paul S. Aisen, MD¹

¹Alzheimer's Therapeutics Research Institute, University of Southern California, San Diego, CA, USA, ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, ³Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, ⁴Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA

Saturday, October 27

1.45 - 2.00 p.m.

OC32 - Detecting brain amyloid status using fully automated plasma A β biomarker assays

Sebastian Palmqvist¹, Shoren Janelidze, PhD¹; Erik Stomrud, MD PhD¹; Henrik Zetterberg, MD PhD²; Johann Karl, PhD³; Niklas Mattsson, MD PhD¹; Kaj Blennow, MD PhD²; Udo Eichenlaub, PhD³; Oskar Hansson, MD PhD¹

¹Clinical Memory Research Unit, Lund University, Sweden, ²Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden, ³Roche Diagnostics GmbH, Penzberg, Germany

2.00 - 2.15 p.m.

OC33 - Concordance of florbetapir (18F) PET and Elecsys[®] β -Amyloid(1-42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD

Timo Grimmer, MD¹, Christina Rabe, PhD², Mercedita Navarro, PhD², David Clayton, PhD², Ekaterina Manuilova, MSc³, Udo Eichenlaub, PhD³, Jillian Smith, BSc⁴, Susanne Ostrowitzki, MD, PhD², Lee Honigberg, PhD², Tobias Bittner, PhD⁵

¹Department of Psychiatry, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, ²Genentech, Inc., South San Francisco, CA, USA, ³Roche Diagnostics GmbH, Penzberg, Germany, ⁴Roche Products Ltd, Welwyn Garden City, UK, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland

2.15 - 2.30 p.m.

OC34 - Development of A β , tau and cognitive changes during the time course of sporadic Alzheimer's disease

Niklas Mattsson, MD, PhD¹, Oskar Hansson, MD, PhD¹, Michael W. Weiner, MD², Philip S. Insel, MS^{1,2}

¹Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, ²Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, CA, USA

2.30 - 2.45 p.m.

OC35 - U.S. POINTER: Study design and trial kick-off

Laura Baker, Ph.D.¹; Mark Espeland, Ph.D.¹, Miia Kivipelto, M.D., Ph.D., Gustavo Jimenez-Maggiara, MBA, Martha Clare Morris, Sc.D., Rema Raman, Ph.D., Scott Rushing, Heather M. Snyder, Ph.D., Jeff Williamson, M.D.¹, Rachel Whitmer, Ph.D., Nancy Woolard¹, Maria C. Carrillo, Ph.D.

¹Wake Forest School of Medicine On Behalf of the U.S. POINTER Study Team

2.45 - 3.00 p.m.

OC36 - Implications for AD clinical trials and opportunities to leverage the first Alzheimer's association U.S. National Best Clinical Practice Guidelines for the evaluation of cognitive behavioral syndromes, Alzheimer's disease and related dementias

Alireza Atri, MD/PhD^{1,2}, Mary Norman, MD³, David S. Knopman, MD⁴, Jason Karlawish, MD⁵, Mary Sano, Ph.D.⁶, Carolyn Clevenger, DNP⁷, Chiadi U Onyike, MD, MHS⁸, Susan Scanland, MSN, CRNP, GNPBC⁹, Paige Lin, PhD¹⁰, James Hendrix, PhD¹¹, Maria C. Carrillo, Ph.D.¹¹, Brad C. Dickerson, MD¹² and Alzheimer's Association Best Clinical Practices Workgroup

¹Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, ²Center for Brain/Mind Medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ³Erickson Living, Dallas, TX, USA, ⁴Mayo Clinic, Rochester, MN, USA, ⁵University of Pennsylvania, Philadelphia, PA, USA, ⁶James J. Peters VA Medical Center, New York, NY, USA, ⁷Emory University, Atlanta, GA, USA, ⁸Johns Hopkins University, Baltimore, MD, USA, ⁹Dementia Connection, Clarks Summit, PA, USA, ¹⁰Tufts Medical Center, Boston, MA, USA, ¹¹Alzheimer's Association, Chicago, IL, USA, ¹²Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA

3.00 - 3.15 p.m.

OC37 - Pros and cons of AD composite endpoints considering recently revised regulatory guidance and 2018 NIA-AA research framework

Michael T. Ropacki, PhD¹, Suzanne Hendrix, PhD²

¹Strategic Global Research & Development, Half Moon Bay, USA, ²Pentara Corporation, Salt Lake City, USA

3.15 - 3.30 p.m.

OC38 - The European Prevention of Alzheimer's Dementia (EPAD); Summary of First Formal Data Lock (EPAD V500.0) and predictors of amyloid status

Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh UK

3.30 - 3.45 p.m.

LB11 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer's disease

Suzanne B. Hendrix, PhD¹, Hilkka Soininen, MD, PhD^{2,3}, Pieter Jelle Visser, PhD^{4,5}, Alina Solomon, MD, PhD^{2,6,7}, Miia Kivipelto, MD, PhD^{2,6,7}, Tobias Hartmann, PhD^{8,9} on behalf of the LipiDiDiet clinical study group

¹Pentara Corporation, Salt Lake City, UT, USA, ²Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, ³Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, ⁴Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, ⁵Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden, ⁷Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, 14152 Huddinge, Sweden, ⁸Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, ⁹Department of Experimental Neurology, Saarland University, Homburg, Germany

3.45 p.m.

End of conference

- **Theme 1. Clinical trials: Methodology** pages 22 - 24
P21, P45, P54, P59, P61, P82, P86, P90 to P101 and LBP1 to LBP12
- **Theme 2. Clinical trials: Results** pages 25 - 27
P7, P12, P13, P15, P16, P18, P36, P80, P109 to P112 and LBP13
- **Theme 3. Clinical trials: Imaging** pages 28 - 29
P10, P35, P62, P76, P113 to P124 and LBP21 to LBP24
- **Theme 4. Clinical trials: Biomarkers including plasma** pages 30 - 34
P1, P4, P22, P28, P30, P39, P44, P57, P64 to P66, P73, P78, P81, P125 to P139 and LBP25 to LBP40
- **Theme 5. Clinical trials: Cognitive and functional endpoints** pages 35 - 38
P2,P3, P8,P9, P19, P25 to P27, P53, P67, P69, P71, P74, P77, P83, P140 to P149 and LBP41 to LBP46
- **Theme 6. Cognitive assessment and clinical trials** pages 39 - 42
P6, P14, P24, P29, P33, P34, P41, P42, P47 to P52, P55, P63, P68, P70, P72, P75, P87 to P89, P150 to P159, P162 and LBP47 to LBP52
- **Theme 7. Behavioral disorders and clinical trials** page 43
P32, P37, P43, P163 and LBP53
- **Theme 8. Health economics and clinical trials** page 44
P17, P40, P58, P164
- **Theme 9. Epidemiology and clinical trials** pages 45 - 46
P17, P38, P46, P165 to P168 and LBP54 to LBP56
- **Theme 10. Clinical Trials: Animal Models** page 47
P102 to P104 and LBP58
- **Theme 11. New therapies and clinical trials** pages 48 - 49
P5, P11, P20, P23, P56, P60, P79, P84, P85, P105 to P108 and LBP59 to LBP62

Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI

Ryoko Ihara, MD¹, Kazushi Suzuki, MD¹, Atsushi Iwata, MD², Takeshi Iwatsubo, MD^{1,3}, the Japanese Alzheimer's Disease Neuroimaging Initiative

¹The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan, ²Department of Neurology, The University of Tokyo, Tokyo, Japan, ³Department of Neuropathology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research

Jacobo Mintzer, MD, MBA¹, Mike Splaine², Erin Beck, MPH³

¹Research and Innovation Center, Roper St. Francis, Charleston, SC, USA; ²Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, ³Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, ³Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of alzheimer's biomarkers: β -amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform

Satya Nandana Narla¹, Amanda Dider¹, Ming Hu¹, Tina LV², Yuan Xueling² and Martine Florent¹

¹Immunology Department, Covance Central Laboratories, Indianapolis, USA, ²Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer's disease

Alessandro Trebbastoni, MD, PhD¹, Marco Canevelli, MD, PhD¹, Giuseppe Bruno, MD¹, Carlo de Lena, MD¹, Letizia Imbriano¹, Fabrizia D'Antonio, MD¹, Laura Pieroni¹

¹Department of Human Neuroscience, «Sapienza» University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance

Jacobo Mintzer, MD, MBA¹, Mike Splaine², Erin Beck, MPH³

¹Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, ²Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, ³Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, ³Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais

Catherine Adnet-Bonte, MD¹, Brigitte Leprince¹, Laetitia Breuilh, PhD^{2,3}, Florence Pasquier, MD, PhD^{2,3}

¹Meotis, Centre Hospitalier Universitaire de Lille, France, ²Neurology Department, Centre Hospitalier Universitaire de Lille, France, ³Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer's presentation

Jaime Perales, PhD¹, MPH; W Todd Moore, MS¹, Mariana Ramirez, LMSW¹; Linda Lara, BA²; Erica Davis, BA³; Jason Resendez, MS⁴; Eric D Vidoni, PhD¹

¹University of Kansas Medical Center, Kansas-USA, ²Guadalupe Center, Kansas City-USA, ³Don Bosco Senior Center, Kansas City-USA, ⁴LatinosAgainstAlzheimer's Coalition, Chevy Chase-USA U1171, Univ Lille

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer's disease (AD)

John Alam¹, Kelly Blackburn¹, Niels Prins^{2,3}, Philip Scheltens²

¹EIP Pharma Inc., Cambridge, MA, USA, ²Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, ³Brain Research Center, Amsterdam, NL

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX[®]2-73 for the Treatment of Early Alzheimer's Disease Together with Precision Medicine Genetic Biomarkers

Stephen Macfarlane, MBBS FRANZCP¹, Michael Kornhauser BPharm¹, Ella Modini BSc¹, Harald Hampel, MD PhD², Stephan Toutain MS³, Christopher Missling PhD³

¹HammondCare Dementia Centre, NSW, Australia, ²Sorbonne University, Paris, France, ³Anavex Life Sciences Corp., New York, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study

Marieke Cajal-Berman, PhD¹, Jessica Branning², Vishnukartik Nitta, MS²

¹Bioclinica Research, Orlando, FL, USA, ²ClinCloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials

Alberto Benussi, MD^{1*}, Antonella Alberici, MD^{1*}, Clarissa Ferrari, MD^{2*}, Valentina Cantoni, MS^{1,3}, Valentina Dell'Era, MD¹, Rosanna Turrone, MS¹, Maria Sofia Cotelli, MD⁴, Giuliano Binetti, MD², Barbara Paghera, MD⁵, Giacomo Koch, MD^{6,7}, Barbara Borroni, MD¹, Alessandro Padovani, MD, PhD¹

*These authors contributed equally to this work.
¹Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ³Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, ⁴Neurology Unit, Ospedale Vallecampaonica, Esine, Brescia, Italy, ⁵Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy, ⁶Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy, ⁷Stroke Unit, Policlinico Tor Vergata, Rome, Italy

P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trialsKenneth Stanley¹, Carolina Rubel¹, Lynne Hughes¹¹IQVIA Project Leadership Unit**P95 - CSF biomarkers outcomes in the ETHERAL AD study**Harald Hampel^{1,2,3,4}, Carlos Buesa⁵, Tamara Maes⁵, Mabel Arevalo⁵, Michele Lufino⁵, Roger Bullock⁵¹AXA Research Fund & Sorbonne University Chair, Paris, France, ²Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France, ³Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225 Paris, France, ⁴Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, ⁵Oryzon Genomics SA, Barcelona, Spain**P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer's Disease**Preciosa M. Coloma¹, Stephanie J. B. Vos², Isabelle Bos², Andy Simmons³, Rik Vandenberghe⁴, Philip Scheltens⁵, José Luis Molinuevo^{6,7}, Flavio Nobili⁸, Sebastiaan Engelborghs^{9,10}, Giovanni Frisoni^{11,12}, Gaël Chetelat¹³, Alberto Lleó¹⁴, Anders Wallin¹⁵, Julius Popp^{16,17}, Pablo Martinez-Lage¹⁸, Gonzalo Duran-Pacheco¹, Pieter Jelle Visser^{2,5}, Mark F Gordon¹⁹, Gerald Novak²⁰¹Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, ²Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, ³Institute of Psychiatry, Kings College, London, UK, ⁴University Hospital Leuven, Leuven, Belgium, ⁵Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Alzheimer's disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain, ⁷Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, ⁸Clinical Neurology, Department of Neurosciences (DINO GMI), University of Genoa and IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ⁹Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium, ¹⁰Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, ¹¹University of Geneva, Geneva, Switzerland, ¹²IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ¹³Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France, ¹⁴Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁵University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, ¹⁶Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, ¹⁷Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, ¹⁸CITA-Alzheimer Foundation, San Sebastian, Spain, ¹⁹Teva Pharmaceuticals, Malvern, PA, USA, ²⁰Janssen Pharmaceutical Research and Development, Titusville, NJ, USA**P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders**Roger Bullock¹, David Rotllant², Michele Lufino², Cristina Mascaro², Carlos Buesa², Tamara Maes², Sonia Gutierrez², Marta Valverde³, Tony Ramos³¹Oryzon Genomics, Barcelona, Spain, ²Vall D'Hebron Hospital, Barcelona, Spain**P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer's disease trials?**Piers Kötting, MBA¹, Kris Beicher², Adam Smith³, Clare Shaw, PhD²¹University of Exeter Medical School, Exeter, UK, ²University of Leeds, Leeds, UK, ³Institute of Neurology, University College London, London, UK**P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer's disease**Smiljana Ristic, MD¹, Mercè Boada, MD, PhD², Nathalie Pross, PhD¹, Danielle Abi-Saab, PsyD¹, Szofia Bullain, MD¹, Mirjana Andjelkovic, PhD¹, Paul Delmar, PhD¹, Carsten Hofmann, PhD¹, Alison Searle, BSc³, Monika Baudler, PhD¹, Paulo Fontoura, MD, PhD¹, Rachele Doody, MD, PhD⁴¹F. Hoffmann-La Roche Ltd, Basel, Switzerland, ²Barcelona Alzheimer Treatment and Research Center, Barcelona, Spain, ³Roche Products Ltd, Welwyn Garden City, UK, ⁴Genentech, Inc., South San Francisco, CA, USA**P100 - Study enrollment and Alzheimer's disease pathology in relation to cohort type and participant characteristics in the EPAD Registry**Lisa Vermunt, MD¹, Graciela Muniz-Terrera, PhD^{2,3,4}, Lea ter Meulen, MSc¹, Colin Veal, PhD⁵, José Luis Molinuevo, MD, PhD⁶, Pierre-Jean Ousset, MD^{7,8}, Niels D Prins, MD, PhD^{1,9}, David Porteous, PhD², Craig W Ritchie, PhD², Philip Scheltens, MD, PhD¹, Gerald Luscan, MSc¹⁰, Anthony J Brookes, PhD⁵, Pieter Jelle Visser, MD, PhD¹¹¹VU University Medical Center, Amsterdam, Netherlands, ²University of Edinburgh, Edinburgh, Scotland, ³University of Victoria, Victoria, Canada, ⁴University of Cambridge, Cambridge, England, ⁵University of Leicester, Leicester, England, ⁶Barcelona Beta Research Center, Barcelona, Spain, ⁷Clinic University Hospital, Barcelona, Spain, ⁸CHU Toulouse, Gérontopôle and INSERM UMR 1027, Toulouse, France, ⁹Brain Research Center, Amsterdam, Netherlands, ¹⁰Pfizer, Paris, France, ¹¹Maastricht University, Maastricht, Netherlands**P101 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes**Richard E. Kennedy, MD, PhD¹, Guoqiao Wang, PhD², Mackenzie E. Fowler, MPH³, Gary R. Cutter, PhD⁴, Lon S. Schneider, MD, MS⁵¹Department of Medicine, University of Alabama at Birmingham, USA, ²Division of Biostatistics, Washington University, St. Louis, USA, ³Department of Epidemiology, University of Alabama at Birmingham, USA, ⁴Department of Biostatistics, University of Alabama at Birmingham, USA, ⁵Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA

Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer's disease clinical development

Olga Uspenskaya-Cadoz¹, Yuliya Nigmatullina², Kenneth Stanley³, Chaitanya Alamuri², Penny Randall¹, Sam Khinda³, Lanhui Wang², Mengting Yang², Carolina Rubel³, Lynne Hughes³, Tao Cao², Michelle O'Keefe², Nikhil Kayal²

¹IQVIA CNS Center of Excellence; ²IQVIA Analytics Center of Excellence; ³IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation

Karen Holdridge, MPH¹, Roy Yaari, MD¹, Brian A. Willis, PhD¹, Isabella Velona, MS¹, Paul Aisen, MD², Reisa Sperling, MD³

¹Eli Lilly and Company, Indianapolis, USA, ²University of Southern California, San Diego, USA, ³Brigham and Women's Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?

Karen Holdridge, MPH¹, Roy Yaari, MD¹, Brian A. Willis, PhD¹, Isabella Velona, MS¹, Susan Mills², Randall Bateman²

¹Eli Lilly and Company, Indianapolis, USA, ²Washington University, Saint Louis, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?

Sean Stanton¹, Dan Davis⁴, Vishnukartik Nitta, MS², Jessica Branning, BS², John Dwyer, JD³, Jason Bork, MBA³, James Taylor⁵, and George Vradenburg, JD⁶

¹LifeCore Solutions, LLC, ²ClinCloud, LLC, ³Global Alzheimer's Platform, ⁴Bioclinica Research, ⁵Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia

Kenneth Rockwood^{1,2}, Justin Stanley¹, Taylor Dunn¹, Susan E Howlett^{1,2}

¹DGI Clinical Inc., Halifax, NS, Canada, ²Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer's disease prevention: an effective recruitment strategy for preventive trials

Isabelle Carrie, PhD¹, Julien Delrieu, MD^{1,2,3}, Françoise Lala, MD¹, Christophe Hein, MD¹, Delphine Pannetier, PhD¹, Pierre Jean Ousset, MD^{1,2,3}, Bruno Vellas, MD, PhD^{1,2,3}

¹Gerontopole, Toulouse University Hospital, Toulouse-France, ²Inserm Unit 1027, Toulouse, France, ³University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer's disease

Lars Lau Raket, PhD¹

¹H. Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer's Disease

Delia A. Gheorghe, MSc¹, Sarah Bauermeister, PhD¹, John Gallacher, PhD¹

¹University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults

Alette Wessels, PhD¹, Adrian Schembri, DPsych², Pav Kalinowski, PhD², Reisa Sperling, MD³, Roy Yaari, MD¹, Paul Aisen, MD⁴, David Barfield, MS¹, Scott Andersen, MS¹, John R. Sims, MD¹, A4 Study Team, Paul Maruff, PhD²

¹Eli Lilly and Company, Indianapolis, IN, USA, ²Cogstate Ltd, New Haven, Connecticut, CT, USA, ³Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ⁴Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials

Lucianne Dobson PhD¹, Miguel Rosa Grilo MD¹, Catherine Mummery PhD, FRCP¹

¹Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer's Disease Study

Adam Butler¹, Denis Curtin, PhD¹, Mackenzie Johnson¹, and Jeff Lee¹

¹CRF Bracket, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer's disease

Steven E. Arnold, MD¹, Rebecca A. Betensky, PhD²

¹Massachusetts General Hospital and Harvard Medical School, Boston, USA, ²Harvard T.H. Chan School of Public Health, Boston, MA

Theme 2. Clinical trials: Results

P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer's disease and depressive symptoms: interim results of an observational study

Eduardo Cumbo MD¹, Silvia Cumbo MD¹, Salvatore Torregrossa PsyD¹, Daniela Migliore PsyD¹

¹Neurodegenerative Disorders Unit, ASP, ²Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer's Disease (CPAD) consortium's vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database

Volker D. Kern, PhD¹, Stephen P. Arneric, PhD¹, Maria C. Carrillo, PhD², James Hendrix, PhD², Billy Dunn, MD³, Stacie Weninger, PhD⁴, Jeffrey A. Kaye, MD⁵, Daniel R. Karlin, MD⁶, Lisa H. Gold, PhD⁷, Michael Gold, MD⁸, Samantha Budd Haeberlein, PhD⁹, Molly Shea, PhD¹⁰, George VradenburgII, Daniela J. Conrado, PhD¹, and Klaus Romero, MS, MD¹

¹Critical Path for Alzheimer's Disease Consortium, Critical Path Institute, Tucson, AZ, USA, ²Alzheimer's Association, Chicago, IL, USA, ³U.S. Food and Drug Administration, Silver Spring, MD, USA, ⁴F-Prime Biomedical Research Initiative, Cambridge, MA, USA, ⁵Oregon Health & Science University, Portland, OR, USA, ⁶Pfizer, Boston, MA, USA, ⁷Merck & Co., Inc., Kenilworth, NJ, USA, ⁸AbbVie, North Chicago, IL, USA, ⁹Biogen, Cambridge, MA, USA, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ¹¹UsAgainstAlzheimer's, Washington, DC, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer's disease: A post-hoc analysis of a multicenter, randomized trial

Yun Jeong Hong, MD, PhD^{1,2}, Hyun Jeong Han, MD, PhD³, Young Chul Youn, MD, PhD⁴, Kyung Won Park, MD, PhD⁵, Dong Won Yang, MD, PhD⁶, Sang Yun Kim, MD, PhD⁷, Hwa Jung Kim, MD, PhD⁸, Ji Eun Kim, MD, PhD⁹, Jae-Hong Lee, MD, PhD¹, the ODESA study group

¹Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ²Biomedical research institute, Pusan National University Hospital, Pusan, ³Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan, ⁴Neurology, Chung-Ang University Hospital, Seoul, ⁵Neurology, Dong-A University College of Medicine, Busan, ⁶Neurology, The Catholic University of Korea, Seoul, ⁷Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam, ⁸Preventive Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ⁹Neurology, University of Ulsan College of Medicine, Gangneung Asan Medical Center, Gangneung, Korea

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers

Stephen Lowe¹, Jeffrey Dage², Ann Cleverley³, Albert Lo², Elizabeth S. LaBell², Hakop Gevorkyan⁴, Stanford Jhee⁵, Larry Huffman², Boris Calderon², Brian A. Willis²

¹Lilly Centre for Clinical Pharmacology, Singapore, ²Eli Lilly and Co, Indianapolis, IN, ³Eli Lilly and Co, Erl Wood, UK, ⁴California Clinical Trials Medical Group, Inc., ⁵PAREXEL Early Phase, Glendale, CA, USA

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses

Stefan Viktor Vormfelde, MD/PhD¹, Nicole Pezous¹, Gilbert Lefèvre, PhD¹, Carine Kolly, PhD¹, Ulf Neumann, PhD¹, Pierre Jordaan, MD², Guenter Heimann, PhD², Mike Ufer, MD/PhD¹, Ana Graf, MD², Eric Legangneux, MD¹

¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors

Kenneth Rockwood, MD^{1,2}, Justin Stanley, BSc¹, Susan E Howlett, PhD^{1,2,3}

¹DGI Clinical Inc., Halifax, NS, Canada, ²Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, ³Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase 1 Clinical Studies in Alzheimer's Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640

Marc Cantillon, MD¹, Hiroyuki Shimada, MD, PhD², Kenichiro Sugiyama, Phar.B.³, Wei Sun, Ph.D.¹, Yoshiumi Ouchi, M Eng³, Katsuyoshi Tsukii, MSc¹, Gemma Clark, RGN RM⁴

¹Kyowa Kirin Pharmaceutical Development, Inc., USA, ²Osaka city university hospital, Osaka, Japan, ³Kyowa Hakko Kirin Co., Ltd., Japan, ⁴Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase 1b study

Philipp von Rosenstiel MD¹, Tianle Chen, PhD¹, John O'Gorman, PhD¹, Min Yee, PharmD¹, Carmen Castrillo-Viguera, MD, PhD¹, Claudia Prada, MD¹, Christoph Hock, MD², Roger M Nitsch, MD², Samantha Budd Haeberlein, PhD¹, Alfred Sandrock, MD, PhD¹

¹Biogen, Cambridge, MA, USA, ²Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

P109 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?

Kathleen M. Hayden, PhD¹; José A. Luchsinger, MD²; Stephen R. Rapp, PhD¹; Delilah R. Cook, CCRP¹; Rebecca H. Neiberg, MS¹; Judy L. Bahnsen, BA¹; Tara D. Beckner¹; Jerry M. Barnes, MA¹; and Mark A. Espeland, PhD¹ for the Look AHEAD MIND Study Group

¹Wake Forest School of Medicine, Winston-Salem, USA, ²Columbia University, New York, USA

P110 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTL0018318 in healthy volunteers

Tim Tasker MBBS¹, Jan Liptrot PhD¹, Charlotte Bakker PhD², Ellen 't Hart PhD², Erica Klaassen PhD², Samantha Prins MD², Thalia van der Doef PhD², Mike Walker², Giles A. Brown PhD¹, Alastair Brown PhD¹, Miles Congreve PhD¹, Malcolm Weir PhD¹, Fiona H. Marshall PhD¹, David M. Cross PhD⁴, Geert Jan Groeneveld MD, PhD², Pradeep J. Nathan PhD^{1,3}

¹Sosei Heptares, Cambridge UK, ²Centre for Human Drug Research (CDHR), Leiden, Netherlands, ³Department of Psychiatry, University of Cambridge, UK, ⁴Cross Pharma Consulting Limited, Cambridge, UK

P111 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings

Jessica B. Langbaum, PhD¹, Jason Karlawish, MD², Scott Roberts, PhD³, Angela Bradbury, MD², Scott Kim, MD, PhD⁴, Elisabeth McCarty Wood, MS², Carolyn Langlois, MA¹, Fonda Liu PharmD⁵, Marie-Emmanuelle PhD⁶, Marie-Laure Rouzade-Dominguez, PhD⁶, Angelika Caputo, PhD⁶, Mauritz Bezuidenhout, M.Sc⁶, Cristina Lopez-Lopez, MD, PhD⁶, Ana Graf, MD⁶, Pierre N. Tariot, MD¹, Eric M. Reiman, MD¹

¹Banner Alzheimer's Institute, Phoenix, USA, ²University of Pennsylvania, Philadelphia, USA, ³University of Michigan, Ann Arbor, USA, ⁴National Institutes of Health, Bethesda, USA, ⁵Novartis Pharmaceuticals Corporation, East Hanover, USA, ⁶Novartis Pharma AG, Basel, Switzerland

P112 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer's disease with low dose hydromethylthionine

Bjoern Schelter, PhD^{1,2}, Claude Wischik, MD, PhD^{1,2}

¹Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, ²TauRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI

Carine Federspiel, MD^{1,2}, Elisabeth Bourkel, PhD¹, Jean-Paul Steinmetz, PhD^{1,2}

¹Centre for memory and mobility, ZithaAktiv, Luxembourg, ²ZithaSenior, Research&Development, Luxembourg

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses

Daniel Alkon, PhD¹, LJ Wei, PhD², Richard Thompson, PhD³

¹Neurotope, Inc, ²Harvard University, ³Johns Hopkins University

LBP15 - Enterovirus might be involved in Alzheimer's disease - results from a phase IIa trial evaluating Apovir, an antiviral drug combination

Lars-Olof Wahlund, MD, PhD¹, Lars Lindqvist MD, PhD², Mikael Åström MSc, PhD³, Jacob Westman PhD⁴, Roger Bullock MD, PhD⁵, Suzanne Hendrix⁶, Nina Lindblom, PhD⁴

¹Karolinska University Hospital, Huddinge, Sweden, ²Karolinska University Hospital, Huddinge, Sweden, ³StatCons, Limhamn, Sweden, ⁴Apodemus AB, Solna, Sweden, ⁵Roger Bullock Consulting Ltd, Swindon, UK, ⁶Pentara Corporation, Salt Lake City, USA

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer's disease

Samer Kaba, MD¹, Casey Lynch¹, Mark Ryder, DMD², Ira Goodman, MD³, Steve Thien, MD⁴, Steve Dominy, MD¹

¹Cortexyme, S. San Francisco, CA, ²UCSF, San Francisco, CA, ³Bioclinica, Orlando, FL, ⁴Pacific Research Network, San Diego, CA

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up

Miquel Aguilar MD, PhD¹ and Paquita Soler, Nurse¹

¹Àptima Mutua Terrassa, Catalunya, SPAIN

LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial

Carmen Valcarce, PhD¹, Imogene Dunn, PhD¹, Tom Soeder, MS², and Aaron Burstein, PharmD¹

¹Viv Therapeutics LLC, High Point, NC, USA, ²CATO Research Ltd., Durham, NC, USA

LBP19 - Aducanumab 48-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer's disease

Philipp von Rosenstiel, MD¹, Samantha Budd Haeberlein, PhD¹, Carmen Castrillo-Viguera, MD¹, Tianle Chen, PhD¹, John O'Gorman, PhD¹, Raj Rajagovindan, PhD¹, Dakshaben Patel, PhD², Guanfang Wang, PhD³, Spyros Chalkias, MD¹, LeAnne Skordos PharmD¹, Claudia Prada, MD¹, Christoph Hock, MD⁴, Roger M Nitsch, MD⁴, Alfred Sandrock, MD, PhD¹

¹Biogen, Cambridge, MA, USA, ²Biogen, Maidenhead, UK, ³Cytel, Cambridge, MA, USA, ⁴Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer's Disease Colombia Trial

Pierre N. Tariot^{1*}, Francisco Lopera^{2*}, Kaycee M. Sink³, Nan Hu³, Heather Guthrie³, Jillian Smith⁴, William Cho³, Jessica B. Langbaum¹, Ronald G. Thomas⁵, Kewei Chen¹, Yi Su¹, Dhruvan Goradia¹, Pradeep Thiyyagura¹, Paul S VanGilder¹, Ji Luo¹, Valentina Ghisays¹, Wendy Lee¹, Michael H. Malek-Ahmadi¹, Hillary D. Protas¹, Yinghua Chen¹, Carole Ho³, Shehnaaz Suliman³, Sergio Alvarez⁵, Yakeel T. Quiroz⁶, Robert Paul⁷, Silvia Rios Romanets^{2**}, Eric M. Reiman^{1**}, and the API ADAD Colombia Trial Group

¹Banner Alzheimer's Institute, Phoenix, AZ, USA, ²Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO, ³Genentech Inc., South San Francisco, CA, USA, ⁴Roche Products Ltd, Welwyn Garden City, UK, ⁵University of California, San Diego, CA, USA, ⁶Hospital Pablo Tobon Uribe, Medellin, CO, ⁷Harvard Medical School and Massachusetts General Hospital, Boston MA, USA

Theme 3. Clinical trials: Imaging

P10 - Diagnostic accuracy of [18F]FC119S PET for identifying Alzheimer's disease

Byung Hyun Byun, MD, PhD¹, Sang Moo Lim, MD, PhD¹

¹Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea

Yu Yong Choi¹, Byeong C. Kim², Seong-Min Choi², Kee Hyung Park³, Kyu Yeong Choi¹, Kun Ho Lee^{1,4}

¹National Research Center for Dementia, Chosun University, Gwangju, South Korea, ²Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea, ³Department of Neurology, Gachon University College of Medicine, Incheon, South Korea, ⁴Department of Biomedical Science, Chosun University, Gwangju, South Korea

P62 - Impact of cerebral blood flow changes on 18F-florbetaben SUVR. A simulation study

Santiago Bullich, PhD¹, Norman Koglin, PhD¹, Susan De Santi, PhD², Georg A. Becker, PhD³, Audrey Perrotin, PhD¹, Aleksandar Jovalekic, PhD¹, Andrew Stephens, MD, PhD¹, Henryk Barthel, MD, PhD³, Osama Sabri, MD, PhD³

¹Piramal Imaging GmbH, Berlin, Germany, ²Piramal Pharma Inc., Boston, MA, USA, ³Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia

Ruben Smith, MD, PhD¹, Alexander F Santillo, MD, PhD¹, Maria Landqvist Waldö, MD, PhD², Oskar Hansson, MD, PhD^{1,3}

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, ²Memory Clinic, Ängelholm Hospital, Ängelholm, Sweden, ³Memory Clinic, Skåne University Hospital, Malmö, Sweden

P113 - Predicting amyloid burden from cognitive assessment

Donald R. Royall, MD^{1,4}, Raymond F. Palmer, PhD³ for the Alzheimer's Disease Neuroimaging Initiative

¹Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, ²Department of Medicine, UTHSCSA, San Antonio, Texas, USA, ³Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, ⁴South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer's disease

Michela Rampini, MS^{1,2}, Moira Marizzoni, PhD¹, Valentina Garibotto, MD³, Michela Pievani, PhD¹, Giovanni B Frisoni, MD^{1,3}

¹IRCCS Fatebenefratelli, Brescia, Italy, ²University of Brescia, Brescia, Italy, ³Geneva University Hospitals, Geneva, Switzerland

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data

David Scott, PhD¹, Katarzyna Adamczuk, PhD¹, Beth Gorman, BS CNMT², Maureen Runkle, BS CNMT R.T.(N.)², Joyce Suhy, PhD¹ and the Alzheimer's Disease Neuroimaging Initiative

¹Bioclinica, Newark, CA, USA, ²Bioclinica, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?

Sergey Shcherbinin, PhD¹, Michael J. Pontecorvo, PhD², Ming Lu, MD, MS, MPH², Michael D. Devous Sr, PhD², A. Joshi, PhD², Sudeepti Southekal, PhD², Emily C. Collins, PhD^{1,2}, Adam S. Fleisher, MD², Mark A. Mintun, MD^{1,2}

¹Eli Lilly & Co, Indianapolis, IN, USA, ²Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans

Gemma Salvadó MSc¹, Chris Foley PhD², Elisabetta Grecchi, PhD^{2,3}, M. Jorge Cardoso, PhD^{4,5}, Isadora Lopes-Alves, PhD⁶, Pawel Markiewicz, PhD⁵, Carles Falcon, PhD¹, Mark Battle MSc², Adriaan A. Lammertsma, PhD⁶, Mark Schmidt, MD, PhD⁷, José Luis Molinuevo MD PhD¹, Frederik Barkhof, MD, PhD^{5,6}, Juan Domingo Gispert, PhD¹

¹BarcelonaBeta Brain Research Center, Barcelona, Spain, ²GE Healthcare, Amersham, United Kingdom, ³IXICO, London, United Kingdom, ⁴King's College London, London, United Kingdom, ⁵University College London, London, United Kingdom, ⁶VU Medical Center, Amsterdam, The Netherlands, ⁷Janssen Pharmaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer's disease

Andrew Stephens¹, Andre Mueller¹, Santiago Bullich¹, Mathias Berndt¹, John Seibyl², Olivier Barret², Jennifer Madonia², Heiko Kroth³, Andrea Pfeifer³, Andreas Muhs³, Gilles Tamagnan², Kenneth Marek², Ludger Dinkelborg¹

¹Piramal Imaging, Berlin, Germany, ²Invicro, New Haven, USA, ³AC Immune SA, Lausanne, Switzerland

P119 - Cut-off for 18F-flutemetamol SUVr with white matter reference region

Katarzyna Adamczuk, PhD¹, David Scott, PhD¹, Ben Newton, PhD³, Joyce Suhy, PhD¹, Michael Egan, MD², Cyrille Sur, PhD²

¹Bioclinica, Newark, CA, USA, ²Merck Sharp & Dohme, Kenilworth, NJ, USA, ³General Electric Health Care, Amersham, UK

P120 - Amyloid PET Imaging in a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with UB-311

Hui Jing Yu¹, Hui-Chen Chen¹, Jacob Hesterman², Jack Heimann², Sean Holmes², Alex Whittington², Xue Wang², Roger Gunn², Ajay Verma¹

¹United Neuroscience, Inc. Hauppauge, NY, USA, ²Invicro, A Konica Minolta Company, Boston, MA, USA

P121 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study

Andrea Pilotto^{1,2} and Francesca Schiano di Cola¹, MD and, MD; Enrico Premi¹, MD; Roberto Grasso¹ PsyD, Rosanna Turrone¹, PsyD; MD; Stefano Gipponi¹, MD, Andrea Scalvini¹, MD; Elisabetta Cottini¹, Barbara Paghera³, Laura Bonanni⁴, PhD; MD; Maria Cristina Rizzetti², PhD; Barbara Borroni¹, MD; Alessandro Padovani¹, PhD, MD

¹Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²Parkinson's Disease Rehabilitation Centre, FERB ONLUS S. Isidoro Hospital, Trescore Balneario (BG), Italy, ³Nuclear Medicine Unit, University of Brescia, Brescia, Italy, ⁴Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy

P122 - Very early detection and treatment monitoring of Alzheimer's Disease in the retina by multimode, hyperspectral confocal scanning ophthalmoscopy

Daniel L. Farkas, PhD^{1,2}, Fartash Vasefi, PhD¹, Jeanne M. Fontana, MD, PhD¹

¹The Brain Window, Inc., Sherman Oaks CA, USA, ²University of Southern California, Los Angeles CA, USA

P123 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume

Mirza Faisal Beg, PhD¹, Da Ma, PhD¹, Karteek Popori¹, Mahadev, MD², Lei Wang, PhD³

¹School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada, ²Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

P124 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer's Disease Neuroimaging Initiative

Eddie Stage¹, Diana Svaldi PhD¹, Sophie Sokolow PhD MPharm^{2,5,6}, Shannon L. Risacher PhD¹, Krisztina Marosi², Kwangsik Nho PhD¹, Jerome I Rotter MD^{3,4}, Andrew J. Saykin PsyD¹, Liana G. Apostolova MD MS¹

¹Indiana Alzheimer Disease Center, Indianapolis, IN, USA, ²UCLA School of Nursing, Los Angeles, CA, USA, ³Division of Genomic Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA, ⁴Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA, ⁵UCLA Brain Research Institute, Los Angeles, CA, USA, ⁶UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

Late Breaking Posters

LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer's Disease

Sheng-Min Wang, MD, PhD¹, Yoo Hyun Um, MD, PhD², Chang-Uk Lee MD, PhD³, and Hyun Kook Lim, MD, PhD³

¹Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ²St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea, ³Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer's dementia in an Asian Clinic Cohort

Nagaendran Kandiah

National Neuroscience Institute, Singapore

LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

Susan Abushakra MD¹, Luc Bracoud MS², Joël Schaerer², Aidan Power MD¹, John Hey PhD¹, David Scott PhD³, Joyce Suh PhD³, Martin Tolar MD PhD¹ & the Alzheimer Disease Neuroimaging Initiative (ADNI)

¹Alzheon Inc., Framingham, MA, USA, ²Bioclinica, Lyon France, ³Bioclinica, Newark CA, USA

LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study

Gregory Klein¹, Ruben Smith², Sebastian Palmqvist², Niklas Mattsson², Danielle van Westen², Olof Strandberg², Jonas Jögi², Tomas Ohlsson², Edilio Borroni¹, Preciosa Coloma¹, Erik Stomrud², Oskar Hansson²

¹Roche Pharma Research and Early Development, Basel, Switzerland, ²Clinical Memory Research Unit, Lund University, Sweden

Theme 4. Clinical trials: Biomarkers including plasma

P1 - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment

Shani Waninger, Ph.D.¹, Chris Berka¹, Amir Meghdadi, Ph.D.¹, David Salat, M.D.² and Ajay Verma, M.D., Ph.D.³

¹Advanced Brain Monitoring, Inc., Carlsbad, CA, ²MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA, ³United Neuroscience, Dublin, Ireland

P4 - High correlation in the A β 40 and A β 42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS

José A. Allué, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.

Araclon Biotech S.L., Via Hispanidad 21, 50.009, Zaragoza, Spain

P22 - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI

Kazushi Suzuki MD, PhD¹, Ryoko Ihara MD, PhD¹, Atsushi Iwata MD, PhD¹, Takeshi Iwatsubo MD, PhD¹, Kenji Ishii MD², Takeshi Ikeuchi MD, PhD³, Ryozo Kuwano MD, PhD³, Japanese Alzheimer's Disease Neuroimaging Initiative

¹The University of Tokyo, Tokyo, Japan, ²Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Niigata University, Niigata, Japan

P28 - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β -Amyloid 1-40 assays

Manu Vandijck, Martine Dauwe, Rosina Degrieck, Els Huyck, Nathalie Le Bastard, Geert Jannes, Vesna Kostanjevecki

Fujirebio Europe NV, Ghent, Belgium

P30 - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888

Norman Relkin MD, PhD¹, Dan Li PhD², Joshua Costin PhD², David Wyatt MD³

¹Relkin Consulting LLC, Harrington Park, NJ 07640, ²HerbalScience Group, Naples FL, USA, ³Syneos Health, Miami FL, USA

P39 - Diagnostic biomarkers' clinical applicability in early onset Alzheimer's disease

Neus Falgàs¹, Raquel Sánchez-Valle¹, Mircea Balasa^{1,2}, Sergi Borrego¹, Magdalena Castellví¹, Adrià Tort-Merino¹, Jaume Olives¹, Beatriz Bosch¹, Guadalupe Fernández¹, Francisco Lomeña³, Núria Bargalló⁴, Albert Lladó¹

¹Alzheimer's disease and other cognitive disorders Unit. IDIBAPS. Hospital Clínic de Barcelona, ²Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, ³Nuclear Medicine Department. IDIBAPS. Hospital Clínic de Barcelona, ⁴Image Diagnostic Centre. IDIBAPS. Hospital Clínic de Barcelona

P44 - Inverse association between A β 42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study

Itziar de Rojas, MSc¹, Judith Romero, MSc², Octavio Rodríguez-Gomez, MD¹, Pedro Pesini, PhD², Angela Sanabria, PhD¹, Alba Pérez-Cordon, MSc¹, Carla Abdelnour, MD¹, Isabel Hernández, MD, PhD¹, Maitee Rosende-Roca, MD¹, Ana Mauleón, MD¹, Liliana Vargas, MD¹, Montserrat Alegret, PhD¹, Ana Espinosa, PhD¹, Gemma Ortega, PhD¹, Silvia Gil, MD, PhD¹, Marina Guitart, MSc¹, Anna Gailhagane, MSc¹, Miguel Angel Santos-Santos, MD, PhD¹, Sonia Moreno-Grau, MSc¹, Oscar Sotolongo-Grau, PhD¹, Susana Ruiz, MN¹, Laura Montreal, MLT¹, Elvira Martín, MSc¹, Esther Pelejà¹, Francisco Lomeña, MD, PhD³, Francisco Campos, PhD³, Assumpta Vivas, MD⁴, Marta Gómez-Chiari, MD⁴, Miguel Angel Tejero, MSc⁴, Joan Giménez, MD⁴, Virginia Pérez-Grijalba, PhD², Marta Marquí, MD, PhD¹, Gemma Monté-Rubio, PhD¹, Sergi Valero, PhD¹, Adelina Orellana, PhD¹, Lluís Tàrraga, MSc¹, Manuel Sarasa, PhD², Agustín Ruiz, MD, PhD¹, Mercè Boada, MD, PhD¹, on behalf of the FACEHBI study

¹Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, ²Araclon Biotech@. Zaragoza, Spain, ³Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain, ⁴Departament de Diagnòstic per la Imatge. Clínica Corachan, Barcelona, Spain

P57 - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study

Oskar Hansson MD PhD^{1,2}, Katharina Zink MSc³, Simone Wahl PhD³, Monika Widmann ChTech⁴, Sandra Rutz PhD³, Maryline Simon PhD⁵, Kaj Blennow MD PhD^{6,7}, Erik Stomrud MD PhD^{1,2}

¹Clinical Memory Research Unit, Lund University, Malmö, Sweden, ²Memory Clinic, Skåne University Hospital, Malmö, Sweden, ³Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, ⁴Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Mannheim, Germany, ⁵Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland, ⁶Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ⁷Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

P64 - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer's Disease biomarkers in clinical practice

Oskar Hansson MD PhD^{1,2}, Erik Stomrud, MD PhD^{1,2}, Sandra Rutz PhD³, Valeria Lifke PhD³, Ekaterina Bauer MBA PhD³, Udo Eichenlaub PhD³, Richard Batrla MD PhD⁴, Ekaterina Manuilova MSc⁴, Mehmet Can Mert PhD⁴, Simone Wahl PhD⁴, Kaj Blennow, MD, PhD^{5,6}

¹Clinical Memory Research Unit, Lund University, Malmö, Sweden, ²Memory Clinic, Skåne University Hospital, Malmö, Sweden, ³Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany, ⁴Centralised & Point of Care Solutions, Roche Diagnostics International, Rotkreuz, Switzerland, ⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ⁶Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer's DiseaseShu Yu^{1*}, Yue-Ping Liu²

¹State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province 710000, China, ²Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China, *: Corresponding author

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic targetLynn Bekris¹, Rumana Akhter¹, Yvonne Shao¹, Maria Khrestian¹, Giana D'Aleo¹, Shane Formica¹, James B. Leverenz²

¹Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, ²Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer's centreNataliya Mikhaylova¹, Lubov Androsova²

¹MD, PhD Geriatric psychiatry Department, Mental health research centre, Moscow, Russia, ²PhD, Immunology laboratory, Mental health research centre, Moscow, Russia

P78 - Modifiable Alzheimer's risk biomarkersChristine Ganzer¹, Alon Seifan, MD², Krista Ryon³, Elizabeth Maiche MCMSc, PA-C⁴

¹Hunter College, NY, ²NeuroWell Free, Ft. Lauderdale, Florida, ³Hunter College, NY, ⁴NeuroWell Free, Ft. Lauderdale, Florida

P81 - Serum NFL, TAU, GFAP and UCHL-1 in Alzheimer disease patients with different decline profileMélissa Jacob, MD^{1,2,3}, Aleksandra Maceski, PhD³, Stiene Rickaert PhD³, Audrey Gabelle MD, PhD^{1,2,4}, Sylvain Lehmann MD, PhD^{2,3}

¹Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France, ²Université de Montpellier, MUSE, Montpellier, France, ³Inserm U1183 IRMB, Montpellier, France, ⁴Inserm UI061, La Colombière Montpellier University Hospital, Montpellier, France

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluidEugeen Vanmechelen, PhD¹, Jeroen Vanbrabant, PhD¹, Naomi De Roeck, BcS2, Maria Bjerke, PhD², Sebastiaan Engelborghs, MD, PhD^{2,3}, Ann De Vos, PhD¹

¹ADx NeuroSciences NV, Ghent, Belgium, ²Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, ³Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down Syndrome. A cross-sectional studyMaria Carmona-Iragui, MD, PhD^{1,2,3}, Bessy Benejam, MSc², Susana Fernández, MD², Laura Videla, MSc^{1,2,3}, Isabel Barroeta, MD, PhD^{1,3}, Daniel Alcolea, MD, PhD^{1,3}, Jordi Pegueroles, MSc^{1,3}, Laia Muñoz, MSc^{1,3}, Olivia Belbin, PhD^{1,3}, Jordi Clarimón, PhD^{1,3}, Mony John de Leon, Ed.D⁴, Sebastián Videla, MD, PhD^{2,5}, Aleksandra Maleska Maceski, MSc⁶, Christophe Hirtz, PhD⁶, Constance Delaby, PhD⁶, Sylvain Lehmann, PhD⁶, Rafael Blesa, MD PhD^{1,3}, Alberto Lleó, MD, PhD^{1,3}, Juan Fortea, MD PhD^{1,2,3}

¹Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau- Biomedical Research Institute Sant Pau- Universitat Autònoma de Barcelona, Spain, ²Barcelona Down Medical Center. Fundació Catalana de Síndrome de Down, Barcelona, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain, ⁴New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry, New York, USA, ⁵Clinical Research Support Unit, Bellvitge University Hospital / Bellvitge Biomedical Research Institute (IDIBELL) / University of Barcelona, Barcelona, Spain, ⁶Université de Montpellier, CHU de Montpellier, INSERM U1183, Montpellier, France

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer's Disease in carriers and non-carriers of the ApoE4 risk alleleRichard Pither PhD³, Ganna Leonenko¹, Rebecca Simms¹, Paula Daunt PhD³, Greg Davidson PhD³, Alex Gibson PhD³, Olusegun Oshota PhD³, Maryam Shoai PhD², Kevin Banks³, Simon M Laws PhD⁴, Zsuzsanna Nagy⁶ and John Hardy, PhD, DSc², Julie Williams PhD^{1,6}, Valentina Escott-Price, PhD^{1,6}

¹Cardiff University, Cardiff, United Kingdom, ²Cytox Ltd, UK, Oxford, United Kingdom, ³UCL Institute of Neurology, London, United Kingdom, ⁴Edith Cowan University, and Cooperative Research Centre (CRC) for Mental Health, Perth, Australia, ⁵University of Birmingham, United Kingdom, ⁶Dementia Research Institute, Cardiff, United Kingdom

P128 - Do short Aβ-peptides impact the time course of cognitive decline? An ADNI analysisMarkus von Kienlin, PhD¹, Paul Delmar, PhD¹, Katharina Buck, PhD², Charlotta Schärfe², Simone Wahl, PhD², Karlheinz Baumann, PhD², Irene Gerlach, PhD¹, Tania Nikolcheva, MD, PhD¹

¹pRED NORD, Roche Innovation Center Basel - Switzerland, ²Biostats and Data Management, Roche Innovation Center Munich - Germany

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer's diseaseSangYun Kim, MD, PhD^{1,2}, Sungmin Kang, MS³, Seong Soo A. An, PhD⁴, Young Chul Youn, MD, PhD⁵

¹Department of Neurology, Seoul National University College of Medicine, ²Clinical Neuroscience Center, Seoul National University Bundang Hospital, ³PeopleBio Company, ⁴Department of Bionano Technology, Gachon Medical Research Institute, Gachon University, ⁵Department of Neurology, Chung-Ang University College of Medicine

P130 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer's disease patients

Giacomo Koch MD, PhD^{1,2}, Caterina Motta MD², Francesco Di Lorenzo MD², Maria Concetta Pellicciari PhD², Sonia Bonni PhD², Silvia Picazio PhD², Carlo Caltagirone MD², Alessandro Martorana MD³

¹Department of Behavioral and Clinical Neurology, ²Santa Lucia Foundation IRCCS, Rome, Italy, ³University of Tor Vergata, Rome, Italy

P131 - Non-core biomarkers (neurofilament light, neurogranin, 14-3-3 and YKL-40) in the Alzheimer's disease continuum, frontotemporal dementia and prion diseases diagnosis

Anna Antonell, PhD¹, Adrià Tort, MSc¹, José Ríos, MSc², Sergi Borrego, MD¹, Mircea Balasa, MD¹, Cristina Muñoz-García¹, Beatriz Bosch, PhD¹, Neus Falgàs, MD¹, Lorena Rami, PhD¹, Kaj Blennow, MD, PhD³, Henrik Zetterberg, PhD^{4,5}, José Luis Molinuevo, MD, PhD¹, Albert Lladó, MD, PhD¹, Raquel Sánchez-Valle, MD, PhD¹

¹Alzheimer's disease and other cognitive disorders Unit, Hospital Clínic. IDIBAPS. Barcelona, Spain, ²Medical Statistics Core Facility, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clínic. Barcelona. Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, ³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, ⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, ⁵Department of Molecular Neuroscience, University College London, London, UK

P132 - Amyloid blood biomarker detect Alzheimer's disease

Klaus Gerwert, Prof. Dr.¹

¹Ruhr-Universität Bochum, Bochum, Germany

P133 - Early diagnosis of Mild Cognitive Impairment and Alzheimer's disease based on salivary lactoferrin

Eva Carro¹, Gorka Orive²

¹Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain, ²Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain

P134 - Exome-sequencing in patients with early-onset Alzheimer's disease and Frontotemporal dementia: causal mutations and genetic variants in risk genes for dementia

Anna Antonell, PhD¹, Raquel Sánchez-Valle, MD, PhD¹, Neus Falgàs, MD¹, Mircea Balasa, MD, PhD¹, Debayan Datta, PhD², Lluís Armengol, PhD², Sergi Borrego, MD¹, Guadalupe Fernández, Beatriz Bosch, PhD¹, Jaume Olives, Cristina Muñoz-García¹, María León¹, Magdalena Castellví¹, Adrià Tort¹, Albert Lladó, MD, PhD¹

¹Alzheimer's disease and other cognitive disorders Unit, Hospital Clínic. IDIBAPS. Barcelona, Spain, ²Genomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat, Spain

P135 - The future of blood-based kinase biomarkers in Alzheimer's disease

Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet

Center of Cognitive Neurology, Lariboisière Hospital, AP-HP, University of Paris Diderot, Paris France

P136 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects

Charlotte E. Teunissen, PhD¹, Elisabeth Thijssen, MSc², Inge M. W. Verberk, MSc², Hugo Marcel Vanderstichele, PhD³, Hans Heijst², Harry Twaalfhoven², Kimberley Mauroo BSc³, Philip Scheltens, MD, PhD⁴, and Erik Stoops, Eng³

¹Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands, ²Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands, ³ADx NeuroSciences, Gent, Belgium, ⁴Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands

P137 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer's Disease

Shu Yu^{1*}, Yue-Ping Liu²

¹State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province China, ²Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province, China. *: Corresponding author

P138 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer's Disease

Jagan A Pillai MBBS PhD^{1,2,3}, James Bena MS⁴, Lynn M Bekris PhD⁵, James B Leverenz MD^{1,2,3}

¹Lou Ruvo Center for Brain Health, ²Neurological Institute and ³Department of Neurology, ⁴Quantitative Health Sciences, ⁵Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

P139 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation

Tharick A. Pascoal MD¹, Sulantha Mathotaarachchi MSc¹, Mira Chamoun PhD², Joseph Therriault BSc¹, Robert Hopewell PhD², Gassan Massarweh PhD², Andrea L. Benedet¹, MSc, BSc, Min Su Kang¹, Serge Gauthier¹, MD, Pedro Rosa-Neto¹, MD, PhD

¹Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada

Late Breaking Posters

LBP25 - Discovery of AN Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain

John A. Heyl¹, Petr Kocis, Jakub Hort^{2,3}, Susan Abushakral, Aidan Power¹, Martin Vyhnaček^{2,3}, Jeremy Y. Yu¹ and Martin Tolar¹

¹Alzheon, Inc., Framingham, MA, USA, ²International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic, ³Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic

LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum

Gregory Penner¹, Soizic Lecocq¹, Anaëlle Chopin¹, Simone Lista^{2,3,4,5}, Andrea Vergallo^{2,3,4,5}, Enrica Cavedo^{2,3,4,5}, Francois-Xavier Lejeune⁴, and Harald Hampel^{2,3,4,5} the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

¹NeoNeuro SAS, Villejuif Bio Park, Villejuif, France, ²AXA Research Fund & Sorbonne University Chair, Paris, France, ³Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Paris, France, ⁴Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225, Paris, France, ⁵Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France

LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer's disease for potential use in clinical trials

Alberto Lleó MD, PhD^{1,2}, Raúl Núñez-Llaves^{2,3}, Daniel Alcolea MD, PhD^{1,2}, Martí Colom-Cadena PhD^{2,3}, Laia Muñoz^{2,3}, Marta Querol-Vilaseca^{2,3}, Jordi Pegueroles^{2,3}, Lorena Rami PhD⁴, Albert Lladó MD, PhD⁴, José L. Molinuevo MD, PhD⁴, Mikel Tainta MD, PhD⁵, Jordi Clarimón PhD^{2,3}, Tara Spire-Jones PhD⁶, Rafael Blesa MD, PhD^{1,2}, Juan Fortea MD, PhD^{1,2}, Pablo Martínez-Lage MD, PhD⁵, Raquel Sánchez-Valle MD, PhD⁴, Àlex Bayés PhD^{7,8}, Olivia Belbin PhD^{2,3}

¹Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, ³Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, ⁴Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁵Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain, ⁶Centre for Discovery Brain Sciences and UK Dementia Research Institute, University of Edinburgh, ⁷Molecular Physiology of the Synapse Laboratory, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain, ⁸Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

LBP28 - Diminished platelet-derived hsa-miR-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer's disease

Katrin Beyer, PhD¹, Ana Gámez-Valero, PhD^{1,2}, Jaume Campdelacreu, MD, PhD³, Dolores Vilas, MD, PhD⁴, Lourdes Ispuerto, MD, PhD⁴, Jordi Gascón-Bayarri, MD³, Ramón Reñé, MD, PhD³, Ramiro Álvarez, MD⁴, Maria P Armengol, PhD⁵, Francesc E. Borràs, PhD²

¹Department of Pathology, Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain, ²REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Spain, ³Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of Neurology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Genomic and Microscopy facilities, Institut Investigació Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona (Barcelona), Spain

LBP29 - Development of polygenic risk scores (PRS) for common neuropathology

Julie Collens, PhD¹, Mike Nalls, PhD¹, Marcel van der Brug, PhD¹

¹Vivid Genomics, Inc. San Diego, CA, USA

LBP30 - The Italian Inter-Societal consensual algorithm for the biomarker-based diagnosis of mild cognitive impairment

Marina Boccardi, PhD^{1,2}, Valentina Nicolosi, MS¹, Cristina Festari, MS^{1,3}, Angelo Bianchetti, MD^{4,5}, Stefano Cappa, MD^{1,6,7}, Davide Chiasserini, PhD^{8,9}, Andrea Falini, MD^{10,11}, Ugo Paolo Guerra, MD^{14,15}, Flavio Nobili, MD¹⁵⁻¹⁷, Alessandro Padovani, MD^{7,18}, Giulia Maria Sancesario, PhD^{9,19}, Francesca Benedetta Pizzini, PhD^{13,20}, Alberto Beltramello, MD^{13,21}, Marcello Ciaccio, MD^{9,22}, Orazio Schillaci, MD^{15,23}, Marco Trabucchi, MD^{5,24}, Fabrizio Tagliavini, MD²⁵, Giovanni Battista Frisoni, MD^{2,26}

¹Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, ²LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, ³University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy, ⁴Medicine and Rehabilitation Department, Istituto Clinico S. Anna, Brescia, Italy, ⁵Italian Psychogeriatric Association (AIP), Brescia, Italy, ⁶NETS Center, Scuola Universitaria Superiore IUSS, Pavia, Italy, ⁷Italian Society of Neurology, Association for the Study of the Dementias (SINDem), Italy, ⁸Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy, ⁹Italian Society of Clinical Biochemistry and Clinical Molecular Biology, Laboratory Medicine (SIBioC), Italy, ¹⁰Division of Neuroscience, IRCCS San Raffaele, Milan, Italy, ¹¹Vita-Salute San Raffaele Università, Milan, Italy, ¹²Neuroradiology Unit, IRCCS San Raffaele hospital, Milan, Italy, ¹³Italian Association of Neuroradiology (AINR), Italy, ¹⁴Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy, ¹⁵Italian Association of Nuclear Medicine (AIMN), Italy, ¹⁶Clinical Neurology, Dept of Neuroscience (DiNOGMI), University of Genoa -Italy, ¹⁷IRCCS Ospedale Policlinico San Martino, Genova, Italy, ¹⁸Neurology Clinic, Department of Clinical and Experimental Sciences, Brescia, Italy, ¹⁹Department of Clinical and Behavioural Neurology, Santa Lucia Foundation, Rome, Italy, ²⁰Department of Neuroradiology, General Hospital, Verona, Italy, ²¹Dipartimento di Diagnostica per Immagini, IRCCS Ospedale Classificato «Sacro Cuore - Don Calabria», Negrar, Verona, ²²Department of Biopathology and Medical Biotechnologies, University of Palermo, Palermo, Italy, ²³Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy, ²⁴Tor Vergata, Rome University, Rome, Italy, ²⁵Division of Neurology V/Neuropathology, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy, ²⁶Memory Clinic, University Hospital, Geneva, Switzerland

LBP31 - Secondary structure of Aβ as blood biomarker

Klaus Gerwert Department of Biophysics Ruhr University Bochum, Germany

LBP32 - BDNF as a biomarker for the effects of p38 MAPK α inhibition on IL-1 β -induced impairment of hippocampal synaptic plasticityJohn Alam MD¹, Charlotte Teunissen PhD², Niels Prins MD PhD^{3,4}, Hui-May Chu PhD⁵, Philip Scheltens MD PhD³¹EIP Pharma Inc, Cambridge MA, USA, ²Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, ³Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, ⁴Brain Research Center, Amsterdam, NL, ⁵Anoixis Corporation, Framingham MA, USA**LBP33 - Impact of pre-analytical sample handling on Elecsys A β 40, A β 42 and tTau immunoassays in plasma**Malgorzata Rozga, PhD¹, Tobias Bittner, PhD², Richard Batrla-Utermann, MD, MBA³, Johann Karl, PhD¹¹Roche Diagnostics GmbH, Penzberg, Germany, ²Genentech, A member of the Roche Group, Basel, Switzerland, ³Roche Diagnostics International AG, Rotkreuz, Switzerland**LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid A β 1-42, A β 1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform**Alberto Lleó^{1,2}, Jordi Pegueroles^{1,2}, Laia Muñoz^{1,2}, Valle Camacho³, Diego López-Mora³, Alejandro Fernández-León³, Nathalie Le Bastard⁴, Els Huyck⁴, Alicia Nadal⁵, Verónica Olmedo⁵, Víctor Montal^{1,2}, Eduard Vilaplana^{1,2}, Rafael Blesa^{1,2}, Juan Fortea^{1,2}, Daniel Alcolea^{1,2}¹Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ²Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas. CIBERNED, Spain, ³Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Fujirebio Europe NV, Gent, Belgium, ⁵Fujirebio Iberia, SLU, Barcelona, Spain**LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?**Sean Stanton¹, Vishnukartik Nitta, MS², Jessica Branning, BS²¹LifeCore Solutions, Winter Park, USA, ²ClinCloud, LLC, Orlando, USA**LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSFs measures**Nenad Bogdanovic¹, Enrico Fantoni² & Gill Farrar²¹Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, ²GE Healthcare Life Sciences. Amersham, UK and Boston, USA**LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer's disease: a pilot study**Robert J. Vassar, PhD¹, Randall J. Bateman, MD², Bruce W. Patterson, PhD³, Justyna A. Dobrowolska Zakaria, PhD¹¹Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, ²Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA, ³Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA**LBP38 - Reliability of a rapid APOE assay for Alzheimer's risk assessment and clinical trial screening**Athene Lee, PhD^{1,2}, William Menard, BA², Gina Tonini, MBA², Louisa Thompson, PhD^{1,2}, Jessica Alber, PhD^{1,2}, Stephen Salloway, MD^{1,2}¹Warren Alpert Medical School of Brown University, Providence, RI, USA, ²Butler Hospital, Providence, RI, USA**LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer's disease**Steven Arnold MD, PhD¹, Bianca A. Trombetta², Becky C. Carlyle, PhD²¹Massachusetts General Hospital and Harvard Medical School, ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA**LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer's disease**Timothy D. Boyd, PhD^{1,2}, Jonathan Woodcock, MD^{1,3}, Stefan Sillau, PhD^{1,3}, Vanesa Adame, BS^{1,2}, Thomas Borges, MD^{1,4}, Ashesh Thaker, MD^{1,4}, Brianne Betcher, PhD^{1,5}, Joseph Daniels, MS^{1,3}, Kate Heffernan, BS¹, Huntington Potter, PhD^{1,2,3}¹Rocky Mountain Alzheimer's Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, ²Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, ³Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, ⁴Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, ⁵Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA

Theme 5. Clinical trials: Cognitive and functional endpoints

P2 - Objectively measured physical activity and cognitive function

Hiroyuki Umegaki¹, Taeko Makino², Kazuki Uemura³, Hiroyuki Shimada⁴, Xian Wu Cheng⁵

¹MD, PhD Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, ²PhD Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, ³Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, ⁴Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, ⁵PhD, Masafumi Kuzuya, MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer's disease: Implications for dentate gyrus activity and neurogenesis

Pascal J. D. Goetghebuer¹, Keith A. Wesnes², Steven D. Targum³

¹Bracket LLC, Reading, UK, ²Wesnes Cognition Ltd, Streatley on Thames, UK, ³Bracket LLC, Boston, US

P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia

Jay Cheol Kwon, M.D.¹, Eung Gyu Kim, M.D.², Jae Woo Kim, M.D.³, Oh Dae Kwon, M.D.⁴, Bong Goo Yoo M.D.⁵, Nam-Gon Kim, M.D.⁶, Nack Cheon Choi, M.D.⁷, Seon young Ahn, M.A., Byung Hwa Lee, M.D.⁸, Myong Jin Kang, M.D.⁹, Dae Seob Choi, M.D.¹⁰, The BKVD Study Group

¹Department of Neurology, Changwon Fatima Hospital, ²Inje University Pusan Paik Hospital, ³Dong-A University Medical Center, ⁴Daegu Catholic University Medical Center, ⁵Kosin University Gospel Hospital, ⁶Gimhae Jungang Hospital, ⁷Gyeongsang National University Hospital, ⁸Department of Radiology, ⁹Dong-A University Medical Center, ¹⁰Gyeongsang National University Hospital

P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline in Seventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study

Jay Choel Kwon, MD, PhD., Kyungsoo Lee, MD, Yohan Jung, MD, PhD., Sungrae Cho, MD, PhD. And Nack-cheon Choi, MD, PhD.

¹Changwon Fatima Hospital, Changwon, Korea, The Republic of, ²Samsung Changwon Hospital, Changwon, Korea, The Republic of, ³Gyeongsang National University Hospital, Chinju, Korea, The Republic of

P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in the AMARANTH study

Alette M. Wessels¹, Lisle R. Kingery², Edward I. Bartolic², Laura E. Nickell³, Jamie A. Mullen³, John R. Sims¹

¹Eli Lilly and Company, Indianapolis, IN, USA, ²Cogstate, New Haven, USA, ³AstraZeneca Pharmaceuticals, Cambridge, MA, USA

P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in Japanese ADNI study

Atsushi Iwata, MD¹, Ryoko Ihara, MD², Kazushi Suzuki, MD², Takeshi Iwatsubo, MD², and the Japanese ADNI¹

¹Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan, ²Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital Tokyo, Japan

P26 - A German version of the "Five Word Test" – Discriminating patients with mild cognitive impairment/mild Alzheimer's disease, healthy controls and patients with depression

Hausner L, MD, Dinu-Biringer R, PhD, Frölich L, MD, PhD

Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment

Shim YongSoo, Jung San

Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

P53 - MMSE screening data quality for Alzheimer's disease studies across countries

Jordan Mark Barbone, BA¹, Todd M. Solomon, PhD², H. Todd Feaster, PsyD¹, Macarena Garcia-Valdecasas Colell, MSc³, & David S. Miller, MD, MA¹

¹Bracket, Wayne, PA, USA, ²Boston University School of Medicine, Boston, MA, USA, ³Bracket, Reading, UK

P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer's disease clinical trials using enhanced eCOA devices

Todd M. Solomon, Ph.D.², Jordan Mark Barbone, B.A.¹, Sarah M. Karas, Psy.D¹, Danielle T. DiGregorio, Psy.D¹, Michael R. Maddock¹, MA David M. Miller, MD¹, H. Todd Feaster, Psy.D¹

¹Bracket, Wayne, PA, USA, ²Boston University School of Medicine, Boston, MA USA

P69 - Neuroplasticity-based visual alertness training and improvements in declining executive functions in healthy older adultsThomas Van Vleet, PhD¹, Joseph DeGutis, PhD^{2,3}, Michelle Voss, PhD⁴¹Research and Development, Posit Science, San Francisco, CA, USA, ²School of Medicine, Harvard University, Boston, MA, USA, ³Boston VA, Boston, MA, USA, ⁴Psychology Department, University of Iowa, Iowa City, IA, USA**P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer's Disease Patients**Kenneth Rockwood, MD^{1,2}, Lisa McGarrigle, PhD^{1,2}¹Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, ²DGI Clinical Inc., Halifax, NS, Canada**P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study**Anzalee Khan PhD^{1,2}, Danny Ulshen BA¹, Alexandra Atkins PhD¹, Danela Balentin BA¹, Adam Vaughan PhD¹, Heather Dickerson PhD¹, Brenda L. Plassman PhD³, Kathleen A. Welsh-Bohmer PhD³, Rich Keefe PhD^{1,3}¹NeuroCog Trials, Durham, NC, USA, ²Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, ³Duke University, Durham, NC, USA**P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials**Selam Negash¹, Christopher Weber¹, Christopher Randolph^{1,2}¹MedAvante-ProPhase, ²Loyola University Medical Center**P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics'**

Gaëstel, Y, Phd, CERDA S., MD

Memory Center, Bagatelle Hospital, Talence, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studiesSietske A. M. Sikkes, PhD^{1,2}, Mark A. Dubbelman, MSc¹, Merike Verrijp, MSc¹, Gonzalo Sánchez Benavides, PhD³, David Facal, PhD⁵, Bruno Dubois, MD, PhD⁴, Wiesje M. van der Flier, PhD^{1,2}, Hanna Jokinen, PhD⁶, Cristina Lojo-Seoane⁵, José Luis Molinuevo, MD, PhD³, Arturo X. Pereiro Rozas, PhD⁵, Craig Ritchie, MD, PhD⁷, Magdalini Tsolaki, MD, PhD^{8,9}, Ya-Huei Wu, PhD¹⁰, Stelios Zygouris, MSc^{8,11}, Stephane Epelbaum, MD, PhD⁴, Philip Scheltens, MD, PhD¹¹Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, ²Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, ³BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, ⁴Hôpital Pitié-Salpêtrière, IM2A, PARIS, France, ⁵Department of Developmental Psychology, University of Santiago de Compostela, Spain, ⁶Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland, ⁷University of Edinburgh, United Kingdom, ⁸1st Department of Neurology, Aristotle University of Thessaloniki, Greece, ⁹Greek Association of Alzheimer's Disease and Related Disorders, Greece, ¹⁰Broca Hospital, Paris, France ¹¹Network Aging Research, University of Heidelberg, Germany**P141 - Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer's Disease (AD): Responder Analyses of Cognitive and Functional Outcomes**Susan Abushakra MD^{*1}, Bruno Vellas MD², Serge Gauthier MD³, Anton Porsteinsson MD⁴, Carl Sadowsky MD⁵, Aidan Power MD¹, Larry Shen PhD⁶, Lu Wang MS⁶, Tim Lin MS⁶, John Hey PhD¹, Martin Tolar MD PhD¹¹*Alzheon, Inc., Framingham, MA, USA, ²University of Toulouse, Toulouse, France, ³McGill University, Montreal, Canada, ⁴University of Rochester, Rochester, New York, ⁵Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, ⁶Pharmapace, Inc., San Diego, CA**P142 - Exploring Genetic Associations of Alzheimer's Disease Loci with Mild Cognitive Impairment Neurocognitive Endophenotypes. Impact on cognitive and functional endpoints**Ana Espinosa, PhD¹, Begoña Hernández-Olasagarre, PhD¹, Sonia Moreno-Grau, MSc¹, Luca Kleineidam, MSc^{2,3,4}, Stefanie Heilmann, PhD^{5,6}, Isabel Hernández, MD, PhD¹, Steffen Wolfgruber, Dipl.-Psych^{7,8}, Holger Wagner, MSc⁷, Maitée Rosende-Roca, MD¹, Ana Mauleón, MD¹, Liliانا Vargas, MD¹, Asunción Lafuente, MD¹, Octavio Rodríguez-Gómez, MD¹, Carla Abdelnour, MD¹, Silvia Gil, MD, PhD¹, Marta Marquié, MD, PhD¹, Miguel A. Santos-Santos, MD, PhD¹, Ángela Sanabria, PhD¹, Gemma Ortega, PhD¹, Gemma Monté, PhD¹, Alba Pérez, MSc¹, Marta Ibarria, MSc¹, Susana Ruiz, MSc¹, Johannes Kornhuber, MD, PhD⁹, Oliver Peters, MD⁹, Lutz Frölich, MD, PhD¹⁰, Michael Hüll, MD¹¹, Jens Wiltfang, MD¹², Martin Scherer, MD¹³, Tobias Luch, Dipl.-Psych¹⁴, Steffi Riedel-Heller, MD¹⁴, Laura Montreal, MSc¹, Pilar Cañabate, PhD¹, Mariola Moreno, MSc¹, Silvia Preckler, MSc¹, Nuria Aguilera, MSc¹, Itziar de Rojas, MSc¹, Adela Orellana, PhD¹, Montserrat Alegret, PhD¹, Sergi Valero, PhD¹, Markus M Nöthen, MD^{2,3}, Michael Wagner, PhD^{4,5}, Frank Jessen, PhD^{4,5,7}, Wolfgang Maier, MD^{4,5}, Lluís Tàrraga, MSc¹, Mercè Boada, MD, PhD¹, Alfredo Ramirez, MD, PhD^{2,3,4,5} and Agustín Ruiz, MD, PhD^{1*}¹Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, ²German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, ³Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, German, ⁴Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, ⁵Institute of Human Genetics, University of Bonn, Bonn, Germany, ⁶Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany, ⁷Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, ⁸Department of Psychiatry and Psychotherapy, University Clinic Erlangen, Erlangen, Germany, ⁹Department of Psychiatry, Charité University Medicine, Berlin, Germany, ¹⁰Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany, ¹¹Center for Geriatric Medicine and Section of Gerontopsychiatry and Neuropsychology, Medical School, University of Freiburg, Freiburg, Germany, ¹²Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany, ¹³Department of Primary Medical Care, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ¹⁴Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, Leipzig, Germany

P143 - Baseline characterization of the European prevention of Alzheimer's dementia (EPAD) longitudinal cohort study (LCS)

Michael T. Ropacki, PhD¹, John Harrison, PhD^{2,3}, Joel Kramer, PsyD³, Christopher Randolph, PhD⁴, Jeffrey Kaye, MD⁵, Bruce Albala, PhD⁶, Karen Ritchie, PhD^{7,8,9}

¹Strategic Global Research & Development, Half Moon Bay, USA, ²Metis Cognition Ltd, UK, ³Alzheimer Center VUmc, Amsterdam, Netherlands, ⁴Department of Neurology Memory and Aging Center, University of California at San Francisco, San Francisco, USA, ⁵Department of Neurology, Loyola University Medical Center, Maywood, USA, ⁶Neurology and Biomedical Engineering, Oregon Health and Science University, Portland, USA, ⁷Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatrie, Montpellier, France, ⁸Faculty of Medicine, University of Montpellier, Montpellier, France, ⁹Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

P144 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer's Disease

Angelika Caputo, PhD¹, Ana Graf, MD¹, Cristina Lopez Lopez, PhD, MD¹, Valery Risson, PhD¹, Giulia Lestini, PhD¹, Neva Coello, PhD¹, Amy Racine, PhD¹, Ines Paule, PhD¹, Luyuan Qi, PhD², Helene Karcher, PhD³

¹Novartis Pharma AG, Basel, Switzerland, ²Analytica Laser, a Certara company, Paris, France, ³Analytica Laser, a Certara company, London, UK

P146 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries

Kirsi Kinnunen PhD¹, Richard Joules, PhD¹, Janet Munro, MPhil¹, Iain Simpson PhD¹, Robin Wolz, PhD^{1,2}, Yves Dauvilliers, MD PhD³

¹IXICO Plc, London, UK, ²Imperial College London, London, UK, ³Sleep Unit, Department Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM 1061, France

P147 - Using DCTclock's clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnesic Mild Cognitive Impairment and probable Alzheimer's Disease

William Souillard-Mandar¹, Braydon Schaible¹, Randall Davis PhD^{1,2}, Rhoda Au PhD³, Dana Penney PhD^{1,4}

¹Digital Cognition Technologies, Inc., Waltham, MA, USA, ²MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, ³Boston University Schools of Medicine and Public Health, Boston, MA, USA, ⁴Lahey Hospital and Medical Center, Burlington, MA, USA

P148 - Advancing Clinical and Biomarker Research in AD: The LEAD Study

Liana G. Apostolova, MD, Paul Aisen, MD, Ani Eloyan, PhD, Anne Fagan, PhD, Tatiana Foroud, PhD, Constantine Gatsonis, PhD, Clifford Jack, MD, Joel Kramer, PsyD, Robert Koeppe, PhD, Andrew Saykin, PsyD, Arthur Toga, PhD, Prashanthi Vemuri, PhD, Gregory Day, MD, MSc, Neill Graff-Radford, MD, Lawrence Honig, MD, David Jones, MD, Sterling Johnson, PhD, Joseph Masdeau, MD, Mario Mendez, MD, Chiadi Onyike, MD, Emily Rogalski, PhD, Steve Salloway, MD, David Wolz, MD, Thomas Wingo, MD, Maria Carrillo, PhD, Brad Dickerson, MD, Gil Rabinovici, MD

P149 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer's Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores

Suzanne Hendrix, PhD¹, Noel Ellison, MS¹, Jessica B. Langbaum, PhD², Kewei Chen, PhD³ and David A. Bennett, MD⁴

¹Pentara Corporation, Millcreek, UT, USA, ²Arizona Alzheimer's Consortium, Phoenix, AZ, USA, ³University of Arizona, Tucson, AZ, USA, ⁴Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study

Nina Coll-Padrós¹, Aleix Sala-Vila^{2,3}, Cinta Valls-Pedret², Mercè Serra-Mir^{2,3}, Montserrat Cofán^{2,3}, Irene Roth², Tania Freitas-Simoes², Mónica Doménech², Lúcia Vaqué-Alcázar⁴, David Bartrés-Faz⁴, Sujatha Rajaram⁵, Joan Sabaté⁵, Emilio Ros^{2,3}

¹Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ²Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona, Spain, ³CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain, ⁴Institut de Neurociències i Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona Spain, ⁵School of Public Health, Loma Linda University, Loma Linda, CA, USA

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer's disease

Suzanne B. Hendrix, PhD¹, Hilka Soininen, MD, PhD^{2,3}, Pieter Jelle Visser, PhD^{4,5}, Alina Solomon, MD, PhD^{2,6,7}, Miia Kivipelto, MD, PhD^{2,6,7}, Tobias Hartmann, PhD^{8,9} on behalf of the LipiDiDiet clinical study group

¹Pentara Corporation, Salt Lake City, UT, USA, ²Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, ³Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, ⁴Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, ⁵Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, ⁶Department of Clinical Geriatrics, NVS, Karolinska Institutet, Huddinge, Sweden, ⁷Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden, ⁸Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, ⁹Department of Experimental Neurology, Saarland University, Homburg, Germany

LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer's Disease Dementia: A Phase I Clinical Trial

Hee Jin Kim, MD, PhD^{1,2}, Kyung Rae Cho, MD^{2,3}, Hyemin Jang, MD, PhD^{1,2}, Jung Il Lee, MD, PhD^{2,3}, Seongbeom Park, MS^{1,2}, Soo Jin Choi⁴, Sung Tae Kim, MD, PhD⁵, Seung Hwan Moon, MD, PhD⁶, Kyung-Han Lee, MD, PhD⁶, Sang Won Seo, MD, PhD^{1,2,7}, Duk L. Na, MD, PhD^{1,2,8}

Departments of ¹Neurology, ³Neurosurgery, ⁵Radiology, and ⁶Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, ²Neuroscience Center, Samsung Medical Center, Seoul, Korea, ⁴Biomedical Research Institute, MEDIPOST Co, Ltd, Seoul, Korea, ⁷Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, ⁸Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects

Michael Mullan, MBBS, PhD^{1,2}, Laila Abdullah, PhD², Heather Langlois², Fiona Crawford, PhD^{1,2}, Anders Wallin, MD³, Suzanne Hendrix, PhD⁴, Kaj Blennow, MD, PhD⁵, Brian Lawlor, MBBS⁶. The NILVAD consortium

¹Archer Pharmaceuticals, Sarasota, FL, USA, ²Roskamp Institute, Sarasota, FL, USA, ³Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, ⁴Pentara Corporation, Salt Lake City, UT, USA, ⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, ⁶Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept?

Marie Mc Carthy¹, Crystal Gon²

¹ICON PLC, Dublin, Ireland, ²Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes

Sarah Bauermeister, PhD and John Gallacher, PhD

University of Oxford, Department of Psychiatry, Oxford, UK

Theme 6. Cognitive assessment and clinical trials

P6 - Evaluation of titers of antibodies against peptides of subunits NR1 and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies

Takahiro Ikura, MD, PhD, Yokohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia

Dong Won Yang¹, Ahro Kim¹, Dong Woo Lee², Hyun Jeong Han³, Jee Hyang Jeong⁴, Jun Hong Lee⁵, Jun-Young Lee⁶, Kee Hyung Park⁷, Kyung Won Park⁸, SangYun Kim⁹, Seong Hye Choi¹⁰, Young Chul Youn¹¹

¹Department of Neurology, Catholic University of Korea, Seoul, Korea, ²Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, ³Department of Neurology, Myongji Hospital, Goyang, ⁴Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, ⁵Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, ⁶Department of Psychiatry and Neuroscience Research Institute, Seoul National University College of Medicine & SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁷Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, ⁸Department of Neurology, ⁹Cognitive Disorders and Dementia Center, Dong-A University College of Medicine, Busan, South Korea, ¹⁰Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ¹¹Department of Neurology, Inha University School of Medicine, Incheon, South Korea, ¹²Department of Neurology, Chung-Ang University Hospital, Seoul, Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment

Seon Young Ryu, MD, PhD¹, Sang Bong Lee, MD, PhD¹, Taek Jun Lee, MD¹, Yu Jin Jung, MD, PhD¹

¹Neurology Department, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment

Pamela Voccia EdS¹, Katherine Kruczek, MS¹

¹Bioclinica Research, The Villages, FL USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up

Ahro Kim¹, Dong Won Yang¹, Dong Woo Lee², Hyun Jeong Han³, Jee Hyang Jeong⁴, Jun Hong Lee⁵, Jun-Young Lee⁶, Kee Hyung Park⁷, Kyung Won Park⁸, SangYun Kim⁹, Seong Hye Choi¹⁰, Young Chul Youn¹¹

¹Department of Neurology, Seoul St. Mary's hospital, Catholic University of Korea, Seoul, Korea, ²Department of Psychiatry, Inje University Sanggye Paik Hospital, Seoul, Korea, ³Department of Neurology, Myongji Hospital, Goyang, ⁴Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, ⁵Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, ⁶Department of Psychiatry, Seoul National University Boramae Hospital, Seoul, Korea, ⁷Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, ⁸Department of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, South Korea, ⁹Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ¹⁰Department of Neurology, Inha University School of Medicine, Incheon, South Korea, ¹¹Department of Neurology, Chung-Ang University Hospital, Seoul, Korea

P34 - A multicentre, pilot study to evaluate an Augmented Reality test (ALTOIDATM) for mild cognitive impairment detection

Mircea Balasa, MD, PhD^{1,2}, Adrià Tort-Merino, MSc¹, Ioannis Tarnanas, PhD^{2,3}, David Bartrés-Faz, PhD⁴, Rory Boyle, MSc⁵, Laura Rai MSc⁵, Rob Whelan, PhD^{2,5}, Raquel Sanchez-Valle, MD, PhD¹

¹Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, Barcelona, Spain, ²Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland, ³Altoïda AG, Lucerne, Switzerland, ⁴Departament de Medicina, Faculty of Medicine and Health Sciences, University of Barcelona, ⁵School of Psychology, Trinity College Dublin, Dublin, Ireland

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects

Georg Adler, Nadja Baumgart

Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian methods to model normative CANTAB cognition data across adulthood

Pasquale Dente¹, Elizabeth Baker¹, Jack Cotter¹, Francesca Cormack¹, Jennifer H Barnett^{1,2}

¹Cambridge Cognition Limited, Cambridge, UK, ²University of Cambridge, Cambridge, UK

P47 - Predicting the course of Alzheimer's

Samuel Iddi, PhD^{1,3}, Dan Li, PhD¹, Wesley K Thompson, PhD², Michael S. Rafii, MD, PhD¹, Paul S. Aisen, MD¹, and Michael C Donohue, PhD¹

¹ATRI, University of Southern California, San Diego, CA, United States, ²Department of Family Medicine and Public Health, University of California, San Diego, USA, ³Department of Statistics, University of Ghana, Legon-Accra, Ghana

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI

Sharon Rosenzweig-Lipson, PhD¹, Richard Mohs, PhD¹, Paul Maruff, PhD², Michela Gallagher, PhD^{1,3} and Arnold Bakker, PhD³

¹AgeGenBio, Inc., Baltimore, MD, USA, ²Cogstate, Ltd., Melbourne, Victoria, Australia, ³Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer's disease studies across countries

Jordan Mark Barbone, BA¹, Todd M. Solomon, PhD¹, H. Todd Feaster, PsyD¹, Macarena Garcia-Valdecasas Colell, MSc³, David S. Miller, MD, MA¹

¹Bracket, Wayne, PA, USA, ²Boston University School of Medicine, Boston, MA, USA, ³Bracket, Reading, UK

P50 - Affective variability predicts cognitive fluctuation and decline in older adults

Edward Zamrini, MD¹, Michael Malek-Ahmadi, PhD², Kathy O'Connor¹, Sharon Schofield¹

¹Banner Sun Health Research Institute, Sun City, USA, ²Banner Alzheimer's Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer's disease

Moon Ho PARK, MD, PhD, Do-Young KWON, MD, PhD

Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMT-black and white predict the white matter hyperintensity of MRI in the community based elderly?

Young Chul Youn, MD, PhD

Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnesic mild cognitive impairment

Elizabeth Baker PhD¹, Peter Annas PhD¹, Giovanni B. Frisoni, MD, PhD^{2,19}, David Bartres-Faz, MD, PhD³, Beatriz Bosch PhD³, José Luis Molinuevo, MD, PhD³, Mira Didic, MD, PhD^{4,5}, Francesca De Anna^{4,5}, Lucilla Parnetti, MD, PhD⁶, Nicola Salvadori PhD⁶, Jens Wiltfang, MD, PhD^{7,15}, Flavio Nobili, MD, PhD⁸, Nicola Girtner, Psy.D⁸, Peter Schönknecht, MD, PhD⁹, Pieter J. Visser, MD, PhD¹⁰, Paolo M. Rossini, MD, PhD¹¹, Paola Chiovenda, MA¹¹, Pierre Payoux, MD, PhD¹², Andrea Soricelli, MD, PhD¹³, Marco Salvatore, PhD¹³, Magda Tsolaki, MD, PhD¹⁴, Jill C. Richardson, PhD¹⁶, Régis Bordet, MD, PhD¹⁷, Olivier Blin, MD, PhD¹⁸, Gianluigi Forloni²⁰ on behalf of the PharmaCog Consortium

¹Cambridge Cognition Ltd, Bottisham, Cambridge, UK, ²Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy, ³Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, University of Barcelona and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain, ⁴Aix-Marseille Université, INSERM, France, ⁵Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France, ⁶Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy, ⁷Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVH-Hospital Essen, University of Duisburg-Essen, Essen, Germany, ⁸Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy, ⁹Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany, ¹⁰Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands, ¹¹Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy, ¹²ToNIC, Toulouse Neuroimaging Center, Université de Toulouse, Inserm, UPS, France, ¹³SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy, ¹⁴Third Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece, ¹⁵Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany, ¹⁶Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK, ¹⁷University of Lille, Inserm, CHU Lille, U1171 – Degenerative and Vascular Cognitive Disorders, Lille, France, ¹⁸Aix-Marseille University, UMR Inserm 1106, Institute Neurosciences Sytemes, Marseille, France, ¹⁹Memory Clinic and LANVIE – Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland, ²⁰Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer's Coordinating Center (NACC) dataset

Ali Tafazzoli, PhD¹, Josh Weng, PhD², Kelly Sutton, PhD³, Michal Litkiewicz, MSc³, Ameya Chavan, BS¹, Mira Krotneva, MSc⁴, Anuraag Kansal, PhD¹

¹Evidera, Bethesda, MD, USA, ²Evidera, Waltham, MA, USA, ³Evidera, London, UK, ⁴Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM

Daniel Lawler MD¹, Stephen Thein PhD¹

¹Pacific Research Network Inc., San Diego, CA, USA

P70 - Strategy or symptom: semantic clustering and risk of Alzheimer's disease

Jamie Ford, MSc¹, Bang Zheng, MSc, MD¹, Barbara Hurtado, M.A, CPsychol¹, Chi Udeh-Momoh, MSc, PhD¹, Geraint Price, MSc, D Clin Psy¹

¹Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes

Adrià Tort-Merino, MSc¹, Jaume Olives, MSc¹, María León, MSc¹, Claudia Peñalosa, PhD², Natalia Valech, MSc¹, Petra Grönholm-Nyman, PhD³, Pablo Martínez-Lage, MD, PhD⁴, Juan Fortea, MD, PhD^{5,6}, José Luis Molinuevo, MD, PhD^{1,7}, Raquel Sánchez-Valle, MD, PhD^{1,8}, Matti Laine, PhD³, Antoni Rodríguez-Fornells, PhD^{2,9,10}, Lorena Rami, PhD^{1,8}

¹Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain, ²Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain, ³Department of Psychology, Åbo Akademi University, FIN-20500 Turku, Finland, ⁴Neurología, Fundación CITA-Alzheimer Fundazioa, Centro de Investigación y Terapias Avanzadas, San Sebastián, Guipúzcoa, España, ⁵Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain, ⁶Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas Neurodegenerativas, CIBERNED, Spain, ⁷Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain, ⁸August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, ⁹Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain, ¹⁰Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain

P75 - Flunks and flukes: recognising unrepresentative performance on cognitive tests

Geraint Price, D Clin Psy¹, Bowen Su, MD¹

¹Imperial College London, UK

P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learningAlexandra S. Atkins¹, Anzalee Khan^{1,2}, Daniel Ulshen¹, John Harrison^{3,4}, Brenda L. Plassman⁵, Kathleen A. Welsh-Bohmer⁵ & Richard S.E. Keefe^{1,6}¹NeuroCog Trials, Durham, NC, ²Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, ³Alzheimer Center, VUmc, Amsterdam, The Netherlands, ⁴oPPN, King's College, London, UK, ⁵Duke University Bryan ADRC, Durham, NC, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University Medical Center, Durham, NC**P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study**Emília Moreira, Psy, MPH, PhD¹, Sónia Martins, Psy, PhD^{1,2}, Luís Filipe Azevedo, MD, PHD^{1,3}, José SilvaCardoso, MD, PhD^{1,4,5}, Lia Fernandes, MD, PhD^{1,2,6}¹Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Portugal, ²Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, ³Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto, Portugal, ⁴Department of Medicine, Faculty of Medicine, University of Porto, Portugal, ⁵Department of Cardiology, S. João Hospital Center, Porto, Portugal, ⁶Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal**P89 - The effect of dizziness in patients with cognitive impairments**

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohortsDonald R. Royall, MD^{1,4}, Raymond F. Palmer, PhD³¹Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, ²Department of Medicine, UTHSCSA, San Antonio, Texas, USA, ³Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, ⁴South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA**P152 - Selection of depression-specific dementia cases with replication in two cohorts**Donald R. Royall, MD^{1,4}, Raymond F. Palmer, PhD³¹Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, ²Department of Medicine, UTHSCSA, San Antonio, Texas, USA, ³Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, ⁴South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA**P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study**Beatriz Valles-González¹ & Vicent Rosell-Clari^{1,2}¹Speech and Language Pathology Clinic. Lluís Alcanyis Foundation-Universitat de Valencia, ²Basic Psychology Department, Universitat de Valencia**P154 - Prediction of APOE ε4 Burden from Cognitive Assessment**Royall DR^{1,4}, Palmer RF³ for the Alzheimer's Disease Neuroimaging Initiative*¹Departments of Psychiatry, ²Medicine, Family & ³Community Medicine, The University of Texas Health Science Center at San Antonio and the ⁴South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)**P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home?**Armelle Leperre-Desplanques¹, Isabelle Hauger², Sylvain Gaulier¹, Antonis Politis³, Shima Mehrabian⁴, Audrey Maillat¹, Pierre Krolak-Salmon¹¹Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMRI028, CNRS UMR 5292, Lyon University, France, ²Résidence Talanssa, Talence, France, ³National and Kapodistrian University of Athens, Athens, Greece, ⁴Clinic of Neurology, UH "Alexandrovska", Medical University, Sofia, Bulgaria**P156 - Cognitive Blackouts in Mild Cognitive Impairment of the Amnesic Type and mild Alzheimer's Dementia**

Georg Adler, Agnies Marczak, Jana Binder, Katharina Gnosa

Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasibility of the neuropsychological battery camcomg-ds for the detection of cognitive decline in people with down syndromeLaura Videla^{1,2,3}, Bessy Benejam¹, María Carmona-Iragui^{1,2,3}, Susana Fernández¹, Isabel Barroeta^{1,2,3}, Sebastián Videla², Alberto Lleó^{2,3}, Rafael Blesa^{2,3}, Juan Fortea^{1,2,3}¹Alzheimer Unit - Down, Down Medical Center, Fundació Catalana Síndrome de Down, ²Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, ³Central Biomedical Research Center (CIBERNED)**P158 - Distinct patterns of cognitive decline between early-onset Alzheimer's disease and late-onset Alzheimer's disease**Adrià Tort Merino, MSc¹, Jaume Olives, MSc¹, Neus Falgàs, MD¹, Mircea Balasa, PhD¹, Magda Castellví, MSc¹, Sergi Borrego, MD¹, Beatriz Bosch, PhD¹, María León, MSc¹, Ana Salinero, MSc¹, Guadalupe Fernández, RN¹, Anna Antonell, PhD¹, Raquel Sánchez-Valle, MD, PhD¹, Lorena Ramí, PhD¹, Albert Lladó, MD, PhD¹¹Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain

PI159 - High level of plasmatic amyloid A β 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up

Audrey Gabelle, MD, Ph.D.^{1,2,3}, Laure-Anne Gutierrez, MSc^{2,3}, Thibault Mura M.D, Ph.D.^{2,3}, Jean-François Dartigues, Ph.D.^{4,5}, Olivier Rouaud, MD⁶, Jean-Charles Lambert Ph.D.^{7,8,9,10}, Catherine Helmer, Ph.D.^{4,5}, Claudine Berr M.D, Ph.D.^{2,3}

¹Memory Research and Resources Center, Montpellier University Hospital, Montpellier, ²Inserm U1061, La Colombière Hospital, Montpellier, ³University of Montpellier, MUSE University, Montpellier, ⁴Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France, ⁵CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France, ⁶CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France, ⁷CHRU de Lille, Lille, France, ⁸INSERM U744, Lille, France, ⁹Institut Pasteur de Lille, Lille, France, ¹⁰Université de Lille Nord de France, Lille, France

PI162 - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects

William R. Shankle, MS, MD^{1,2,3}, Junko Hara, PhD^{1,3}, Jason R. Bock, MA¹, Dennis Fortier, MBA¹, Tushar Mangrola, MS¹, Michael Lee, PhD², Gregory E. Alexander, PhD², William H. Batchelder, PhD², Ronald C. Petersen, MD, PhD⁴, Walter Kremers, PhD⁴

¹Medical Care Corporation, Newport Beach, CA, USA, ²Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA, ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA, ⁴Mayo Clinic, Rochester, MN, USA

Late Breaking Posters

LBP47 - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnesic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial

John W. DenBoer, Ph.D., SMART Brain Aging, Inc

LBP48 - Memory errors of commission rather than errors of omission discern aging and early Alzheimer's disease

Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS

Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

LBP49 - Standard cognitive assessment in the era of biomarkers and disease-modifiers

Marina Boccardi, PsyD, PhD², Stefano Cappa, MD, PhD², Bruno Dubois, MD³, Jean Georges⁴, Matthias Kliegel, PsyD, PhD⁵, Bengt Winblad, MD, PhD⁶, David Salmon, PhD⁷, Giovanni Frisoni, MD^{1,2}, Andreas Monsch, PsyD, PhD⁸, for the Task Force for Harmonizing Neuropsychological Assessment for Dementing Neurodegenerative Disorders

¹LANVIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland, ²IRCCS S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy, ³Dementia Research Center, Hôpital Pitié-Salpêtrière, Paris, France, ⁴Alzheimer Europe, ⁵Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland, ⁶Karolinska University Hospital, Stockholm, Sweden, ⁷Department of Neurosciences, University of California San Diego School of Medicine, United States, ⁸University of Basel, Basel, Switzerland

LBP50 - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study

Alette M. Wessels, PhD¹, Jordan Mark Barbone, BA², Danielle T. DiGregorio, PsyD², David S. Miller, MD, MA², Jamie A. Mullen, MD³, & John R. Sims, MD¹

¹Eli Lilly and Company, Indianapolis, IN, USA, ²Bracket, Wayne, PA, USA, ³AstraZeneca Pharmaceuticals, Cambridge, MA, USA

LBP51 - iPSC model of CHR7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development

Ivanna Ihnatovych¹, Tapan Nayak¹, Aya Ouf¹, Norbert Sule², Barbara Birkaya¹, Lee Chaves¹, Anthony Auerbach¹

¹SUNY at Buffalo, ²Roswell Park Cancer Institute

LBP52 - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways

David Berron, PhD^{1,2,3}, Arturo Cardenas-Blanco, PhD⁴, Daniel Bittner, MD², Coraline D. Metzger, MD, PhD⁵, Annika Spottke, MD^{6,7}, Michael Heneka, MD^{7,8}, Klaus Fließbach, MD^{9,10}, Anja Schneider, MD^{7,8}, Stefan J. Teipel, PhD, MD^{11,12}, Michael Wagner, PhD¹³, Oliver Speck, Prof. Dr.¹⁴, Frank Jessen, MD, Prof.^{7,15}, Emrah Düzel, MD^{4,5} and the DELCODE study group

¹Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, ²University Hospital Magdeburg, Magdeburg, Germany, ³German Center for Neurodegenerative Diseases, Magdeburg, Germany, ⁴German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany, ⁵Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, ⁶Department of Neurology, University Hospital of Bonn, Bonn, Germany, ⁷German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany, ⁸Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Bonn, Germany, ⁹DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany, ¹⁰Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany, ¹¹Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, ¹²German Center for Neurodegenerative Diseases, Rostock, Germany, ¹³Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital, Bonn, Germany, ¹⁴Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany, ¹⁵Department of Psychiatry, University Hospital Cologne, Cologne, Germany

Theme 7. Behavioral disorders and clinical trials

P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer's disease - Study of changes in cerebral blood flow by spect imagingAims

Kiyoshi Kanaya¹, Shine Abe²

¹MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, ²MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)

Timofey L. Galankin, MD, PhD², Anton Y. Bepalov, MD, PhD^{1,2}, Hans J. Moebius, MD, PhD¹

¹EXCIVA, Am, Germany, ²Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

P43 - The effect of dizziness in patients with cognitive impairments

Seunghye Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary's Hospital, the Catholic University of Korea, Incheon, Korea

P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)

Jihye Hwang, MD, PhD², Geon-Ha Kim, MD, PhD³, Hae-Ri Na, MD, PhD⁴, Soo-Jin Cho, MD, PhD⁵, Kyung-Ho Yu, MD, PhD⁶, Do Hoon Kim, MD, PhD⁷, Jae-Hong Lee, MD, PhD⁸, Seong-Hye Choi, MD, PhD⁹

²Department of Neurology, Keimyung University School of Medicine, ³Department of Neurology, Ewha Womans University School of Medicine, ⁴Department of Neurology, Bobath Memorial Hospital, ^{5,6,7}Hallym University School of Medicine, ⁸University of Ulsan College of Medicine, Department of Neurology, ⁹Inha University School of Medicine

Late Breaking Posters

LBP53 - Prevalence of obstructive sleep apnea in Alzheimer's disease patients

Anna Carnes, PhD¹, Carme Jorge¹, MD, Benitez ID^{2,3}, Faride Dakterzada¹, Olga Minguez², Raquel Huerto¹, Montse Pujol², MD, PhD, Anna Gaeta, MD², Alfonso Arias¹, MD, Aurora Gibert¹, Manuel Sanchez de la Torres^{2,3}, MD, PhD, Ferran Barbé^{2,3}, MD, PhD, Gerard Piñol-Ripoll¹, MD, PhD

¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida (Spain), ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

Theme 8. Health economics and clinical trials

P17 - Effect of physical activity on the progression of Alzheimer's disease: the CREDOS study

Seong Hye Choi¹, Jee Hyang Jeong², Eun-Joo Kim³, Kyung Won Park⁴, Bora Yoon⁵, Soo Jin Yoon⁶, Yang-Ki Minn⁷, Young Ju Suh⁸

¹Department of Neurology, Inha University School of Medicine, Incheon, South Korea, ²Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, ³Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, ⁴Department of Neurology, Dong-A Medical Center, Dong-A University College of Medicine, Busan, South Korea, ⁵Department of Neurology, College of Medicine, Konyang University, Daejeon, South Korea, ⁶Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, ⁷Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, ⁸Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients

Kee Hyung Park, MD, PhD¹, Chan-Nyoung Lee, MD, PhD², Hojin Choi, MD, PhD³

¹Department of Neurology, Gachon University, Gil Medical Center, Incheon, Korea, ²Department of Neurology, Korea University College of Medicine, Seoul, Korea, ³Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ

Adeline Rollin-Sillaire, MD^{1,2}, Brigitte Leprince³, Catherine Adnet-Bonte, MD³, Laetitia Breuilh, PhD², Florence Pasquier, MD, PhD^{1,2}

¹Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, ²Excellence Laboratory DISTALZ, Inserm U1171, Univ Lille, ³Meotis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies

Marissa D. Zwan, PhD¹, Derek Flenniken^{2,3}, Shannon Finley, MA², Aaron Ulbricht^{2,3}, Rachel Nosheny, PhD^{2,3}, Wiesje M. van der Flier, PhD¹, Philip Scheltens, MD, PhD¹, Diana Truran-Sacrey², Michael W. Weiner, MD^{2,3}, Niels D. Prins, MD, PhD¹

¹Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, ²Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center, San Francisco, USA, ³UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA

Theme 9. Epidemiology and clinical trials

P17 - Awareness of Alzheimer's dementia as their own disease in Asian Countries

San Jung, [YongSoo Shim](#), SangYun Kim

Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary's Hospital, Seoul, Korea, Department of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoake Integrated Care Study (TOICS)

[Hajime Takechi](#), MD, PhD¹, Akira Tsuzuki, RPT, DMSc², Komaki Matsumoto, Ms³, Hiroyuki Nishiyama, Mr⁴, Masatoshi Ogawa, Mr³, Yoshikiyo Kanada, RPT, DMSc²

¹Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan, ²Faculty of rehabilitation, School of Health Science, Fujita Health University, Aichi, Japan, ³Department of community care, Toyoake city municipal office, Aichi, Japan, ⁴Gyosei Corporation, Tokyo, Japan

P46 - Alzheimer's disease drug development pipeline: 2018

[Jeffrey Cummings](#), MD, ScD¹, Garam Lee, PharmD¹, Aaron Ritter, MD¹, Kate Zhong, MD²

¹Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, ²Global Alzheimer Platform, Washington, D.C., USA

P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer's Dementia (EPAD): network and cluster analyses

[Lucy E Stirling](#), MBChB, MRCPsych¹, Tom C Russ MBChB, PhD, MRCPsych^{1,2}, Graciela Muniz Terrera, PhD¹, Craig W Ritchie MBChB, PhD, MRCPsych¹

¹Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK, ²Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer's Disease

[Samantha C Burnham](#), PhD¹, Preciosa M Coloma, MD, PhD², Teresa J. Christainson³, BS, Jean-François Dartigues, MD, PhD^{4,5}, Rachele Doody, MD, PhD⁶, Oskar Hansson, MD, PhD⁷, Catherine Helmer, MD, PhD^{4,8}, Joseph S Kass, MD, JD⁹, Colin L Masters, MD¹⁰, Sebastian Palmqvist, MD, PhD^{7,11}, Valory N Pavlik, PhD⁹, Ronald C. Petersen, MD, PhD^{3,12}, Rosebud O. Roberts, MB ChB, MS^{3,12}, Maria Vassilaki, MD, MPH, PhD³, Barbara Schauble¹³ and Mary Sano, Ph.D.^{14,15}

¹eHealth, CSIRO Health & Biosecurity, Melbourne, Australia, ²Product Development Personalised Health Care, Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland, ³Department of Neurology, Mayo Clinic, Rochester, MN, USA, ⁴Bordeaux University, Bordeaux, France, ⁵INSERM, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France, ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁷Clinical Memory Research Unit, Lund University, Malmö, Sweden, ⁸INSERM U897, BORDEAUX, France, ⁹Baylor College of Medicine, Houston, TX, USA, ¹⁰The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, ¹¹Department of Neurology, Skåne University Hospital, Lund, Sweden, ¹²Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA, ¹³Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland, ¹⁴Department of Psychiatry, Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ¹⁵James J. Peters VA Medical Center, Bronx, NY, USA

P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults

[Oriol Grau-Rivera](#)¹, Juan Domingo Gispert^{1,2}, Grégory Operto¹, Carles Falcón^{1,2}, Raffaele Cacciaglia¹, Gonzalo Sánchez-Benavides¹, Anna Bugulat¹, Nina Gramunt^{1,3}, Gemma Salvadó¹, Marc Suárez-Calvet¹, Carolina Minguillón¹, Karine Fauria¹, José Luis Molinuevo^{1,3,4}

¹BarcelonaBeta Brain Research Center, Catalonia, Spain, ²Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain, ³CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain, ⁴Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain

P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults

[John Olichney](#), MD¹, Charlie DeCarli, MD¹, Joshua W Miller, PhD², David Johnson, PhD¹, Sarah Tomaszewski-Farias, PhD¹, Bruce Hammock, PhD³, Brittany Dugger, PhD⁴, Lee-Way Jin, MD, PhD⁴, Mary McPhail-Ciufo, DO¹, Robert Soohoo, BS⁵, Dan Mungas, PhD¹, Danielle Harvey, PhD⁶

¹Neurology Department, University of California Davis, Sacramento, CA, USA, ²Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, ³Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, ⁴Pathology Department, University of California Davis, Sacramento, CA, USA, ⁵Psychology Department, University of California Davis, Davis, CA, USA, ⁶Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer's Disease Study and UK Biobank

[Sarah Bauermeister](#), PhD and John Gallacher, PhD

University of Oxford, Department of Psychiatry, Oxford, UK

LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer's disease

Anna Carnes, PhD¹, Benítez ID^{2,3}, Faride Dakterzada¹, Olga Minguez², Raquel Huerto¹, Montse Pujol², MD, PhD, Anna Gaeta, MD², Alfonso Arias¹, MD, Aurora Gibert¹, Manuel Sanchez de la Torres^{2,3}, MD, PhD, Ferran Barbé^{2,3}, MD, PhD, Gerard Piñol-Ripoll¹, MD, PhD

¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, ³Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer's disease: a cohort study in a Health Region of Catalonia between 2002 and 2015

Carnes A, Torres-Bondia, F¹, de Batlle J², Piñol-Ripoll, G¹

¹Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain, ²Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain

Theme 10. Animal model and clinical trials

P102 - Concussive head injury exacerbates Alzheimer's disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma^{1*}, José V Lafuente², Dafin F Muresanu^{3a}, Rudy J Castellani⁴, Mark A Smith⁵, Ala Nozari⁶, Ranjana Patnaik⁷, Z Ryan Tian⁸, Asya Ozkizilcik⁹, Stephen D Skaper¹⁰, Herbert Mössler^{1a}, Aruna Sharma¹

¹International Experimental CNS Injury & Repair (IECNISIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, ²Dept of Neurosciences, University of Basque Country, Bilbao, Spain, ³Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁴"RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, ⁵University of Maryland, Dept. of Pathology, Baltimore, MD, USA, ⁶Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, ⁷Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, ⁸School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, ⁹Dept. Chemistry & Biochemistry & ¹⁰Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, ^{1a}Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy, ^{1b}Ever NeuroPharma, Oberburgau, Austria

P103 - Sleep deprivation aggravates Alzheimer's disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma^{1*}, José V Lafuente², Dafin F Muresanu^{3a}, Rudy J Castellani⁴, Mark A Smith⁵, Ala Nozari⁶, Ranjana Patnaik⁷, Z Ryan Tian⁸, Asya Ozkizilcik⁹, Herbert Mössler¹⁰, Hari S Sharma¹

¹International Experimental CNS Injury & Repair (IECNISIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, ²Dept of Neurosciences, University of Basque Country, Bilbao, Spain, ³Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁴"RoNeuro" Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, ⁵University of Maryland, Dept. of Pathology, Baltimore, MD, USA, ⁶Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, ⁷Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, ⁸School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, ⁹Dept. Chemistry & Biochemistry & ¹⁰Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, ^{1a}Ever NeuroPharma, Oberburgau, Austria

P104 - The effect of crenezumab on beta-amyloid toxicity-induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD

Genentech, Inc., South San Francisco, CA, US

Late Breaking Posters

LBP58 - Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer's Disease models

Fernando Goni, PhD¹, Krystal Herline, PhD¹, Mitchell Marta-Ariza, MSc¹, Frances Prelli, MSc¹ and Thomas Wisniewski, MD¹

¹New York University School of Medicine, New York, USA

Theme 11. New therapies and clinical trials

P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnesic type

Gavrilova S.², Volpina O.¹, Kolykhalov I.², Ponomareva E.², Selezneva N.², Fedorova Y. B., Karaev D.¹, A. V. Kamynin

¹Mental Health Research Center, Moscow, Russia, ²Institute of bioorganic chemistry M.M.Shemaykin and Y.A.Ovchinnikov Russian Academy of Sciences, Moscow, Russia

P11 - 11 β -hydroxysteroid dehydrogenase type I inhibitors pharmacological mechanism of potential therapeutic uses - a systematic review

Sarah Gregory¹, John W. Ketelbey², Tamara Miller², Vincent S Ruffles², Craig W. Ritchie¹

¹University of Edinburgh, Edinburgh, UK, ²Actinogen Medical Ltd, Sydney, New South Wales, Australia

P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer's disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimers Disease

Ramakrishna Nirogi, PhD¹, Jyothsna Ravula, MS¹, Satish Jetta, MS¹, Koteswara Mudigonda, PhD¹, Vinod Kumar Goyal, MS¹, Santosh Kumar Pandey, MS¹, Gopinadh Bhyrapuneni, PhD¹, Renny Abraham, PhD¹, Vijay Benade, MS¹, Pradeep Jayarajan, PhD¹, Anil Shinde, PhD¹, John Ieni, PhD¹ and Venkat Jasti, MS¹

¹Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

P23 - Efficacy and safety of trigriluzole (BHV-4157) in patients with mild to moderate Alzheimer's dementia: T2 PROTECT AD phase 2 study design

Irfan A. Qureshi, M.D.¹, Karen Messer, Ph.D.², Kirsten Erickson, Ph.D.², Robert M. Berman, M.D.¹, Carolyn Revta², Tilman Oltersdorf, M.D.², Branko Huisa, M.D.², Diane Jacobs, Ph.D.², David Salmon, Ph.D.², Doug Galasko, M.D.², Thomas O. Obisesan, M.D.³, Neelum Aggarwal, M.D.⁴, Jacobo Mintzer, M.D.⁵, Judith Heidebrink, M.D.⁶, Amanda Smith, M.D.⁷, Miranda N. Reed, Ph.D.⁸, Holly C. Hunsberger, Ph.D.⁸, Lia Donahue¹, Kimberly Gentile¹, David A. Stock, Ph.D.¹, Vladimir Coric, M.D.¹, Howard Feldman, M.D.²

¹Biohaven Pharmaceuticals, Inc., New Haven, CT, USA, ²Alzheimer's Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, ³Howard University, Washington, DC USA, ⁴Rush University Medical Center, Chicago, IL, USA, ⁵Roper St. Francis Hospital, Charleston, SC, USA, ⁶University of Michigan, Ann Arbor, MI, USA, ⁷University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, ⁸Auburn University, Auburn, AL, USA

P56 - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo

Bengt Winblad^{4,6}, Gunnar Nordvall^{2,3,4}, Ping Yan⁵, Johan Lundkvist^{1,2,3,4}, Johan Sandin^{1,2,3,4}, Henrik Biverstål⁴, Henrik Zetterberg⁷, Rebecka Klintonberg³, Mats Ferm³, John R Cirrito⁵, Jin-Moo Lee⁵

¹AlzeCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, ²AlzeCure Foundation, Preclinical Research, Huddinge, Sweden, ³AstraZeneca R&D, CNS & Pain iMed, Södertälje, Sweden, ⁴Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, ⁵Washington University School of Medicine, Dept of Neurology, St Louis, USA, ⁶Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, ⁷Sahlgrenska University Hospital, Clinical Neurochemistry Laboratory, Mölndal, Sweden

P60 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer's disease

Rajnish Kumar, PhD¹, Pavel Pavlov, PhD¹, Bengt Winblad, MD, PhD^{1,2}

¹Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, ²Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice

Francois J. Roman¹, PhD, Johann Meunier¹, PhD, Laura Ceolin¹, PhD, Jean-Marie Butterlin², MS, Guillaume Blivet³, MS, Jacques Touchon⁴, MD, PhD

¹Amylgen, Montferrier-sur-Lez, France, ²Health Optimization Devices B.V., Maastricht, Netherlands, www.cognixtra.com, ³Montpellier, France, ⁴INSERM UI061 & Montpellier University, Montpellier, France

P84 - Clinical Development of AXS-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer's Disease

Herriot Tabuteau, MD¹, Amanda Jones, PharmD¹, Cedric O'Gorman, MD¹

¹Axsome Therapeutics Inc., USA

P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer's disease

Gerson D. Hernandez, MD, MPH¹, Naoko Kono, MPH², Claudia M. Lopez, BS¹, Ron Irwin, PhD³, Kathleen Rodgers, PhD¹, Jimmy Wu, PhD⁴, Rosario Mollo, PhD⁴, Sonia Pawluczyk, MD⁵, Meng Law, MD⁶, Wendy Mack, PhD², Lon Schneider, MD, MS⁵, Roberta D. Brinton, PhD¹

¹Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, ²Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, ³School of Pharmacy, University of Southern California, Los Angeles, CA, USA, ⁴TOMO Pharmacometrics, LLC, San Mateo, USA, ⁵Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, ⁶Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

PI05 - SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer's disease

Benoît Melchior, PhD¹, Carolyn Lai¹, Karen Duong-Polk¹, Amanda Tjitro¹, Lauren Pitzer¹, Joshua Stewart¹, Luis Dellamary¹, Scott Anderson¹, Brian Hofilena¹, Chiao-Wen Chen, PhD¹, Charlene Barroga, PhD¹, Gopi Mittapalli, PhD¹, Sunil KC, PhD¹, Philippe Marchand, PhD¹, and Yusuf Yazici, MD¹

Samumed, LLC, San Diego, USA

PI06 - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease

Ewelina Kulikowski¹, Emily Daze¹, Sylwia Wasiak¹, Dean Gilham¹, Laura M. Tsujikawa¹, Brooke Rakai¹, Stephanie C. Stotz¹, Christopher Halliday¹, Ravi Jahagirdar¹, Norman C. W. Wong¹, Michael Sweeney² and Jan O. Johansson²

¹Resverlogix Corp, Calgary, AB, Canada, ²Resverlogix Inc, San Francisco, CA, USA

PI07 - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy

Fabrizio Piazza, PhD^{1,2,3,4}, on behalf of The iCA β International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia* Jacopo C. DiFrancesco^{1,2,3}, Marialuisa Zedde^{1,5}, Federica Angiulli^{1,3}, Rosario Pascarella⁵, Roberto Marconi⁶, Francesco Perini⁷, Alberto Villarejo-Galende⁸, Mario Cirillo⁹, Bernardino Orlandi¹⁰, Ihara Masafumi¹¹, Mehdi Touat¹², Hagiwara Yuta¹⁶, Juan F. Vázquez-Costa¹⁶, Massimo Caulo¹⁵, Shima Atsushi¹⁶, Alessia Giossi¹⁷, Ricardo Nitri¹⁸, Massimo Musicco^{2,4} *Main Network Collaborators :

¹The inflammatory cerebral amyloid angiopathy and Alzheimer's disease biomarkers (iCA β) International Network, University of Milano Bicocca, Monza, Italy, ²The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy, ³University of Milano Bicocca, Monza, Italy, ⁴National Research Council, Segrate, Italy, ⁵Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Department of Neuroscience, Ospedale Misericordia, Grosseto, Italy, ⁷St. Bortolo Hospital, Vicenza, Italy, ⁸Hospital 12 de Octubre. CIBERNED, Madrid, Spain, ⁹Università della Campania «L. Vanvitelli», Seconda Università degli Studi di Napoli, Italy, ¹⁰S. S. Filippo and Nicola Hospital in Avezzano, L'Aquila, Italy, ¹¹National Cerebral and Cardiovascular Center, Osaka, Japan, ¹²Dana-Farber Brigham and Women's Hospital, Boston, Massachusetts, Insemm U 1127, CNRS UMR 7225, Sorbonne Universités, Paris, France & USA, ¹³St. Marianna University School of Medicine, Japan, ¹⁴Instituto de Investigación Sanitaria la Fe (IIS La Fe), Valencia, Spain, ¹⁵University «G. d'Annunzio», Chieti, Italy, ¹⁶Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁷O.U. of Neurology, ASST Cremona, Italy, ¹⁸University of São Paulo School of Medicine, São Paulo, Brazil

PI08 - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly Corplex™ Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept

Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

Late Breaking Posters

LBP59 - Triple therapy with SUVN-502, a 5-HT₆ antagonist, donepezil and memantine in moderate Alzheimer's disease: Baseline patient characteristics in phase-2a study

Alireza Atri, MD, PhD^{1,2}, Jeffrey L. Cummings, MD, ScD³, John Ieni, PhD⁴, Venkat Jasti, MS⁴, Ramakrishna Nirogi, PhD⁴

¹Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, ²Center for Brain/Mind medicine, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, ³Cleveland Clinic, Las Vegas, NV, USA, ⁴Discovery Research, Suvon Life Sciences, Hyderabad, India

LBP60 - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer's disease: trial design and baseline characteristics of participants

W.J. Herring, MD, PhD¹, P. Ceesay, PhD¹, E. Snyder, PhD¹, D. Bliwise, MD², K. Budd, BS¹, J. Hutzelmann, BS¹, J. Stevens, BS¹, D. Michelson, MD¹

¹Merck & Co. Inc., Kenilworth, NJ, USA, ²Emory University School of Medicine, Atlanta, GA, USA

LBP61 - Neuroprotective effect of a new photobiomodulation technique against amyloid A β 25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer's disease

Guillaume J. Blivet, MS¹, Laura Auboyer, PhD¹, Johann Meunier, PhD², François J. Roman, PhD², Jacques Touchon, MD, PhD^{3,4}

¹REGENLIFE SAS, Montpellier, France, ²Amylgen SAS, Montferrier-sur-Lez, France, ³INSERM U1061, Montpellier, France, ⁴Neurology Department, University of Montpellier, France

LBP62 - Interest of REGENLIFE RGN530 photobiomodulation medical device for the treatment of Alzheimer's disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy

Audrey Gabelle, MD, PhD^{1,2}, Thibault Mura, MD, PhD^{2,3}, Karim Bennys, MD^{1,2}, Sophie Navucet, MS^{1,2}, Martine Flores, MS^{1,2}, Laura Auboyer, PhD⁴, Guillaume J. Blivet, MS⁴, Jacques Touchon, MD, PhD^{1,2}

¹Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France, ²MUSE University, Inserm U1061, Montpellier, France, ³Department of Epidemiologic and Clinical Research, La Colombière Hospital, Montpellier, France, ⁴REGENLIFE SAS, Montpellier, France



Clinical Trials on Alzheimer's Disease

CTAD SPONSORS

CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

Gold Sponsors



General Information


Address

Fairmont Rey Juan Carlos I
& Palacio de Congresos de
Cataluña
Av. Diagonal 661 - 671
Barcelona
Spain 08028



Map of the conference hotel and congress center

Congress venue maps





Conference Room:

All sessions will take place in the Auditorium

Coffee Breaks and Poster Sessions:

Breaks and poster presentations will be held in the dedicated area across from the auditorium.

This year all posters for all the different themes will be presented during the entire conference.

Meet our poster presenters during the coffee breaks.

A poster assistance desk will be available at the entrance to locate the posters.

 **Lunches*:** (only for attendees who purchased the lunch package) will be served next to the Poster Session in a dedicated area please present your badge at the entrance.

**Please note that there is no possibility of buying lunches onsite*

Speaker Ready Room - Preview room - Hours of Operation

- Wednesday, October 24: 1pm to 6pm
- Thursday, October 25: 7:30 am to 6pm
- Friday, October 26: 7:30 am to 6pm
- Saturday, October 27: 7:30 am to 5pm

 **Networking coffee time:** In addition to the regular coffee breaks we suggest that you enjoy a cup of coffee with your peers and increase your networking time around the conference starting times

- Wednesday, October 24: 3:15pm to 4:00pm
- Thursday, October 25: 7:45am to 8:30 am
- Friday, October 26: 7:45am to 8:30am
- Saturday, October 27: 7:45am to 8:30am and 3:00pm to 4:00pm

 **FREE WIFI AVAILABLE AT CTAD**

Network: CTAD2018

Password: CTAD2018

Conference Mobile App

CTAD 2018 has its own Mobile App!

The App will be available for download on October 22, 2018 on the Apple App Store and Google Play (Search CTAD 2018) to be used on your mobile phone but also on large devices like an iPad or laptop computer.

The conference is right at your fingertips: discover the program, read the abstracts, learn more about our speakers, network with other participants and so much more!



Keep in touch

BARCELONA 2018

CTAD Congress

Phone: + 33 (0)4 67 10 92 23

Email: ctad@ant-congres.com

www.ctad-alzheimer.com

Follow us on



[@CTADConference](https://twitter.com/CTADConference)



[CTAD Alzheimer](https://www.linkedin.com/company/ctad-alzheimer)



[CTAD Conference](https://www.facebook.com/CTADConference)

[#CTAD18](https://twitter.com/CTAD18)

www.ctad-alzheimer.com

CTAD Alzheimer 2019

Clinical Trials on Alzheimer's Disease



© iStock

December 4-7, 2019
SAN DIEGO, California

Hilton Bayfront San Diego

Montpellier '08 / Las Vegas '09 / Toulouse '10 / San Diego '11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18

www.ctad-alzheimer.com

Email: ctad@ant-congres.com



MONTPELLIER and TOULOUSE EADC Centers
European Alzheimer's Disease Consortium

Keck School of Medicine of USC
Alzheimer's Therapeutic Research Institute

